










A low-cost, low-intensity contingency management smoking cessation programme with 





19 February 2018 
 
A minor dissertation submitted in partial fulfilment of the requirements for the degree of 




Supervisor: Prof. Harold Kincaid 




















The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 





Tobacco consumption is a pressing global issue, leading to more than five million deaths each 
year. In South Africa, the smoking prevalence rate is stubbornly high, implying that a 
successful smoking cessation programme could have large social benefits, particularly if it 
targets young smokers. Contingency management interventions, which provide cash transfers 
conditional on biochemically-verified abstinence, have been effective in bringing about 
increased smoking cessation rates. However, contingency management programmes are 
typically very costly and involve frequent monitoring. This dissertation presents results of 
randomised controlled trial evaluating a low-cost, low-intensity contingency management 
smoking cessation programme conducted on a sample of treatment-seeking student smokers at 
the University of Cape Town in 2017. There is a statistically significant treatment effect, that 
is robust across multiple specifications, which increases the likelihood of abstinence by 13-
20%. In addition, the programme as a whole decreased the smoking intensity of non-abstainers. 
This study suggests, therefore, that a low-cost, low-intensity contingency management 
smoking cessation programme is efficacious in promoting abstinence amongst treatment-
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Tobacco consumption is a pressing and widespread issue, internationally and in South Africa. 
Tobacco consumption has been identified as one of the leading causes of preventable death, 
with direct tobacco use leading to approximately five million deaths each year (World Health 
Organization (WHO) 2013). In addition, more than 600 000 people die each year as a result of 
second-hand smoke (WHO 2013). Tobacco consumption also has environmental costs: 
cigarette butts are one of the most commonly discarded pieces of waste worldwide and 
contribute approximately 1.69 billion pounds in weight to toxic waste (Eriksen et al. 2015). In 
terms of the economic costs, tobacco consumption raises the burden on the government’s 
budget by increasing health care costs and it is estimated that tobacco-related deaths lead to 
half a trillion dollars of economic damage each year worldwide (WHO 2013). Clearly tobacco 
consumption is a deep social, economic, and public health issue that demands the attention of 
policy makers.  
 
A number of options exist to help control tobacco consumption. On the supply-side, 
governments can regulate the manufacturing, marketing, and sale of tobacco products by 
banning deceptive cigarette labels; prohibiting advertising, promotion, and sponsorship; and 
requiring large, graphic health warning labels (Tobacconomics 2018). On the other hand, to 
control the demand for cigarettes, governments can increase taxes on, and therefore prices of, 
tobacco products. In addition, they can enforce smoke-free policies, i.e., prohibit smoking in 
certain places, such as in or near buildings, restaurants, bars and/or other public spaces (WHO 
2013). Other demand-side information interventions, such as social marketing campaigns, aim 
to decrease consumption by raising awareness about the health and economic consequences of 
tobacco use. Finally, smoking cessation interventions, of which contingency management 
(CM) programmes are one type, have been designed to help smokers quit using tobacco.  
 
In South Africa, the Tobacco Products Control Act (1993) and subsequent amendments (2000, 
2009) define government policy towards tobacco (Campaign for Tobacco-free kids 2017; 
Steyn et al. 2002). These laws govern many aspects of tobacco control, including: restrictions 
on public smoking (e.g., smoking is banned in partially covered outdoor areas and cars carrying 
children under 12); bans on tobacco advertising and sponsorships; and restrictions on the 
labelling and packaging of tobacco products (Campaign for Tobacco-free kids 2017). Largely 
attributed to the tightening controls, tobacco consumption has declined significantly. However, 
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the last few years have seen the smoking rate plateau (Peer et al. 2009). Prevalence rates for 
men and women who smoke daily are 22.2% and 9%, respectively (Eriksen et al. 2015). While 
the male prevalence rate is lower compared to other middle-income countries, the female 
prevalence rate is higher.1 In addition, the South African National Health and Nutrition 
Examination Survey estimates that smoking intensity is 5.9 cigarettes per day for people aged 
15-24 and 8.5 cigarettes per day for the population as a whole (Shisana et al. 2013). 
Consequently, there is still a high mortality rate attributed to smoking in South Africa: the 
percentage of deaths caused by tobacco is 7% for men and 3.8% for women, which corresponds 
to 366 men and 245 women being killed by tobacco every week (Eriksen et al. 2015).  
 
Given the stubbornly high smoking prevalence and smoking intensity rates, alternative 
interventions may be required to help people quit. CM programmes are incentive-based 
interventions which provide participants with rewards contingent on a predetermined 
behavioural change. Several decades of research have demonstrated the effectiveness of CM 
programmes across a range of populations and psychoactive substance addictions, including 
tobacco (Cahill et al. 2015; Petry 2001; Prendergast et al. 2006). Although CM programmes 
are empirically-supported behavioural treatments for tobacco addiction, the cost, complexity, 
and staff burden of CM interventions act as a barrier to their widespread adoption (Secades-
Villa et al., 2014).  
 
Given the potential benefits of this approach, while cognisant of the issues mentioned above, 
this dissertation presents the results of a randomised controlled trial (RCT) investigating the 
efficacy of a low-cost, low intensity CM smoking cessation programme with a sample of 
student smokers at the University of Cape Town (UCT). I focus on two questions: Does a low-
cost, low-intensity CM intervention increase smoking cessation rates and, if not, does it 
decrease the smoking intensity of non-abstainers?  
  
This research is novel because, compared to other CM interventions in the literature, the 
programme provides relatively modest abstinence-contingent cash rewards and has a relatively 
low staff burden. In addition, student smokers are the ideal sample to target for a number of 
reasons: they are easy to recruit and track; their lifetime exposure to cigarettes and their 
                                                
1 Prevalence rates for selected countries are: Brazil – men: 16.6%, women: 11.1%; India – men: 23.2%, women: 
3.2%; Botswana – men: 21.5%, women: 6.1% (Eriksen et al. 2015). 
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smoking intensity tend to be low compared to older smokers so they may be more susceptible 
to an intervention (Mayhew et al. 2000); their relatively low incomes mean that the rewards 
may be more salient; and, if the programme is successful at getting them to quit, the personal 
and societal benefits are large and continue to accrue over time.  
 
This dissertation proceeds as follows: Section 2 discusses different models of addiction and 
provides a review of the theoretical and empirical CM literature. Section 3 outlines the design 
of the CM intervention. Section 4 explains the statistical methodology and Section 5 presents 
the results. Section 6 discusses the results and concludes.  
 
2. LITERATURE REVIEW 
 
In this section I outline the theoretical and empirical CM literature, with particular emphasis 
on the treatment of tobacco addiction. A natural first step is to discuss addiction from an 
economic standpoint. This provides a rationale for the use of CM to treat tobacco addiction and 
a segue into the discussion of the relevant literature.  
 
2.1 Understanding and modelling addiction 
 
The disease model of addiction is a longstanding interpretation of addiction (Heyman 2009). 
The basic argument is that addiction is a disease: substance use produces a disease state typified 
by compulsive drug taking. On this account, addiction is understood to have a biological basis 
such that use of psychoactive substances can convert a voluntary drug user into an involuntary 
one. Adherents of the disease model argue that it provides a humane interpretation of addiction 
and that it leads to better treatment for addicts. The disease model dates back to the 17th century 
and remains a common view among the medical fraternity, the public, and the media (Heyman 
2009, p. 17; Warner 1994). 
 
However, many researchers have challenged the notion that addiction is a disease. Heyman 
(2009) argues that addiction should rather be understood as a disorder of choice, involving 
voluntary behaviour.2 His argument is that addictive drug use involves voluntary behaviour 
                                                
2 Heyman (2009, p. 104) defines voluntary behaviour as “… the degree to which an activity is voluntary is the 
degree to which it systematically varies as a function of its consequences, and the degree to which it is feasible to 
apply such consequences.”  
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since it varies systematically as a function of its costs and benefits: when the costs of addictive 
consumption increase or the benefits decline, addicts reduce or stop consuming their target of 
addiction. Heyman cites particularly convincing evidence from the four largest 
epidemiological studies of addiction conducted in the United States: the Epidemiologic 
Catchment Area study (Anthony and Helzer 1991); the National Comorbidity Survey (Warner 
et al. 1995); the National Comorbidity Survey Replication (Kessler, Berglund, et al. 2005; 
Kessler, Chiu, et al. 2005); and the National Epidemiologic Survey on Alcohol and Related 
Conditions (Stinson et al. 2005). Heyman finds that the majority of addicts quit using their 
targets of addiction by their early thirties and do so without any kind of formal treatment. This 
suggests that as addicts move into adulthood where personal and professional demands are 
typically greater than at younger ages, many addicts successfully manage to quit their targets 
of addiction (Hofmeyr 2015). This implies that addictive consumption is a voluntary behaviour 
that responds to changes in consequences.  
 
The view that addiction is a disorder of choice suggests that CM interventions may be an 
effective form of treatment. CM interventions change the consequences associated with 
consuming the target of addiction by providing abstinence-contingent incentives that increase 
the benefits of abstinence and increase the opportunity cost of consuming the target of 
addiction. If addiction is a voluntary behaviour that varies as a function of its consequences 
then CM interventions could prove to be an effective form of treatment. 
 
This dissertation adopts the view that addiction is a disorder of choice involving voluntary 
behaviour. While this interpretation of addiction appears to stand in direct opposition to the 
view that addiction is an involuntary disease, Ross et al. (2008) argue that the two contradictory 
models of addiction can be reconciled. They argue that addiction can be understood at two 
levels: the molecular and molar (i.e., behavioural) levels. According to Ross et al. (2008), the 
disease model of addiction provides a molecular account of addiction while Heyman’s choice-
based interpretation provides a molar account of addiction.3 Thus, that both the disease and 
choice-based models of addiction contribute to our understanding of addiction and should be 
judged at their respective levels of analysis.  
 
                                                
3 The reconciliation of the disease and choice-based models of addiction is not the focus of this dissertation. See 
Ross et al. (2008) for further details.  
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Given the assumption that addiction is a disorder of choice, I will now examine how economics 
has modelled addiction. I will discuss economic models of addiction that highlight the molar 
scale factors that can result in substance dependence and which provide a theoretical 
justification for the use of CM to treat addiction. While these choice-based accounts provide a 
partial understanding of addiction they are not, as noted above, at odds with a molecular level 
interpretation of addiction.  
 
Becker and Murphy (BM, 1988) developed a theory of rational addiction which assumes that 
agents take into account all past, present, and future implications of their consumption choices 
and implement a consistent plan to maximise their welfare through time (Bernheim and Rangel 
2007). Specifically, agents in the model solve an intertemporal optimisation problem: in each 
time period the agent chooses an optimal mix of addictive and non-addictive goods. In the case 
where the agent chooses to consume the addictive good, his/her stock of addictive capital 
increases. As the stock of addictive capital increases, the short-term welfare of the agent 
increases and this makes addictive consumption more attractive in the future while lowering 
long-term welfare.  
 
The BM model employs an additively-separable intertemporal utility function with an 
exponential discount factor and thus agents in the model make time-consistent choices.4 This 
means that agents either choose to consume the addictive good or not: they either consume the 
addictive good now and enjoy the short-term benefit of addictive consumption while suffering 
the long-term costs, or they abstain now and enjoy the long-term benefits that arise due to a 
decrease in the stock of addictive capital. In the case where agents decide to consume the 
addictive good, they will do so until they have run out of money; they will not deviate from 
this plan unless there is some exogenous shock such as a change in price (Hofmeyr 2015).  
 
Addicts are commonly observed to regret their choices and tend to expend resources to prevent 
or limit their consumption of addictive goods. In addition, the typical course of addiction 
involves multiple unsuccessful quit attempts, before final abstention (Ross 2010). This 
suggests that addicts make time-inconsistent choices with regard to addictive consumption, 
which conflicts with the BM model’s assumption of time consistency. The BM model’s 
                                                
4 Loosely, time consistency means that an agent’s ranking of different consumption bundles does not change 
through time. In other words, if the agent prefers bundle A to bundle B at time point t, she will also prefer A to B 
at all other time points (Hofmeyr 2015). 
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inability to account for the observed time-inconsistent choice behaviour of addicts implies that 
the model is too restrictive.  
 
Numerous economic models of addiction have subsequently been developed which improve 
our understanding of addiction by accounting for time-inconsistent choice behaviour. Broadly, 
these are dual system and dual self models. These models are either diachronic (Bénabou and 
Tirole 2004; Gruber and Köszegi 2001), synchronic (Benhabib and Bisin 2004; Bernheim and 
Rangel 2004), or both (Fudenberg and Levine 2006, 2011, 2012). Dual system models are 
typically synchronic: multiple systems or processes compete for control of behaviour at the 
same time. In contrast, dual self models are usually diachronic: each self has full control of the 
agent’s cognitive and other capacities at a single point in time but there is a succession of selves 
over time. These models adopt different mechanisms to account for time-inconsistent choice 
behaviour5 and, in doing so, incorporate the behavioural patterns of addictive consumption 
mentioned previously.  
 
The economic models of addiction I have discussed have clear implications for policy. The 
BM rational choice model implies that there is no room for government intervention because 
any restriction on consumption of the addictive good, except those reducing negative 
externalities associated with consumption of the addictive good, would be welfare reducing 
(Becker and Murphy 1988, p. 691). In contrast, the dual self and dual system models, which 
better account for the observed behaviour of substance-dependent people, suggest that addicts 
may benefit from interventions to curb their substance use (Hofmeyr 2015). They suggest that 
an addict who exhibits time-inconsistent choice behaviour (i.e., in the present decides to 
consume the target drug because the net benefit is positive, but also wants to quit using the 
addictive substance) may benefit from commitment devices (e.g., commitment contracts for 
abstinence, checking into a rehabilitation centre) and other interventions that adjust their cost-
benefit calculus with regard to addictive consumption. CM is one example of a policy 
intervention that alters the intertemporal cost-benefit trade-off that the addict faces and which 
has proven particularly effective in treating addictive behaviour. The next section discusses the 
theoretical and empirical CM literature.   
 
  
                                                
5 See Hofmeyr (2015) and Ross (2011, 2014a, 2014b) for detailed reviews. 
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2.2 Treating addiction: Contingency management 
 
CM is a method which uses reinforcement, and less commonly punishment, to promote 
behavioural change (Higgins 2010). CM involves identifying an objectively defined target 
behaviour, frequently monitoring that behaviour, and delivering tangible incentives for 
reaching the target behaviour (Alessi and Petry 2014). CM interventions are based on the 
behaviour analysis theoretical framework6 and are most commonly applied to the treatment of 
substance-use disorders.7 According to this framework, drug use and addiction are maintained 
through the reinforcing biochemical effects of the addictive substance and their relationship 
with the environment, e.g., a feeling of euphoria, social inclusion, etc. (Ledgerwood and Petry 
2010; Prendergast et al. 2006). CM programmes can therefore be used to treat substance use 
disorders because they offer incentives for behaviours incompatible with substance use and 
thus compete with the reinforcing attributes of drug use. The behaviour analysis framework 
that underpins CM interventions fits squarely within Heyman’s (2009) choice-based 
interpretation of addiction: both theories view addiction as a behaviour that can be modified 
by changing the consequences of addictive consumption.  
 
While CM has predominantly been used to treat substance use disorders, the approach dates 
back to token economy procedures developed in the 1960s and 1970s. Specifically, tokens, 
exchangeable for other items, were used to reinforce targeted behaviours in the treatment of 
people with chronic mental illness (Higgins et al. 2017; Petry 2001). In the early 1990s, the use 
                                                
6 Behaviour analysis is the study of the behaviour-environment relationships that influence learning (Meredith et 
al. 2014). Specifically, it is concerned with principles of operant conditioning (i.e., learning processes through 
which behaviour is controlled or shaped by its consequences) and the application of these principles to modify 
behaviour (Meredith et al. 2014; Prendergast et al. 2006).  
7 There has been a proliferation of incentive-based programmes targeting health-related behaviours such as weight 
loss, exercise, medication adherence, and abstinence from addictive substances (Cahill et al. 2015; Meredith et al. 
2014). CM and conditional cash transfers (CCTs) are two types of incentive-based interventions that have been 
used to target health-related behaviours. While CM has largely been used to treat substance use disorders, CCTs 
are prominent in development economics and have been used to target behaviour in a wide range of areas, such 
as: education; employment; health and nutrition; empowerment; and savings, investment, and production 
(Bastagli et al. 2016). Higgins (2010) argues that CM and CCT represent a common approach (i.e., using 
contingent reinforcement to promote behaviour change), but are treated as distinct areas of inquiry because they 
evolved out of different intellectual traditions: CM has its foundations in behavioural psychology and CCT in 
microeconomics. He argues that there are bi-directional benefits to integrating the two literatures. According to 
Higgins (2010), CCT could benefit from CM’s extensive behavioural psychology knowledge base and extensive 
research into the effect of moderators of incentive-based interventions (e.g., the magnitude of reinforcement, 
temporal delays between behaviour change and delivery of the reinforcement, etc.). He argues that CM, which 
has been criticised for its lack of widespread dissemination, could benefit from the large and emerging body of 
practical experience that has come from the dissemination of CCT programmes in everyday community practices 
and public policy.  
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of contingent reinforcement as a treatment for substance use disorders gained attention with 
the work of Higgins and colleagues (see Higgins et al. 2017 for a review). They used CM as 
part of multi-element interventions aimed at treating cocaine dependence in outpatients. In 
combination with intensive counselling, these interventions provided cocaine addicts with 
vouchers, exchangeable for retail items, contingent on objective evidence of recent abstinence 
from cocaine use. These interventions proved effective in a context where most other 
treatments had failed to bring about abstinence. Following Higgins and colleagues’ work, 
research into the efficacy of using CM procedures to treat addictive disorders bourgeoned. 
Several decades of research have provided evidence in support of various CM techniques for 
treating a range of psychoactive substance addictions (Cahill et al. 2015; Petry 2001; 
Prendergast et al. 2006). Debate has thus shifted from whether CM interventions are 
efficacious, to the relative success or limitations of the different design features that may 
account for the variation in effect sizes across interventions. The next section outlines the 
design features typical of CM interventions.  
 
2.2.1 The design features of CM interventions 
 
CM interventions vary considerably across a number of dimensions: who is targeted, what 
behaviour is targeted, and the incentives that are provided. I discuss variation along these 
dimensions in what follows. In terms of the targeted population, CM interventions have been 
conducted with community members, worksite employees, and people in a number of other 
institutions (e.g., drug rehabilitation centres, clinics, hospitals, etc.).8 Some CM interventions 
target the behaviour of more than one individual (Meredith et al. 2014). For example, Halpern 
et al. (2015) group individuals into teams of six and provide contingent-rewards to the 
individual for each group member who achieved abstinence from smoking. Such interventions 
draw on social influences to bring about the desired behavioural change (i.e., abstinence).9 
 
In terms of the targeted behaviour, CM interventions treating substance use disorders have 
targeted abstinence from a range of different drugs, including alcohol, illicit drugs, and 
                                                
8 Within these institutions, CM programmes often target special populations such as pregnant women and patients 
diagnosed with pulmonary disease (Cahill et al. 2015). 
9 Behaviour analytic research and theory suggests that targeting a single individual may be more effective: when 
incentives are contingent on an individual’s behaviour, the correspondence between the targeted behaviour and 
the contingent-incentive is more direct and therefore increases the influence that the incentives have over 
behaviour (Meredith et al. 2014). 
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tobacco, where abstinence is generally biochemically verified with a relevant test (Meredith et 
al. 2014).10 Some CM interventions target polydrug abuse rather than a single drug: the 
programmes require abstinence from all drugs and pay out the contingent-incentive if the 
subject provides biological samples that are negative for all targeted drugs.11 Other 
programmes target reduced drug use rather than complete cessation. For example, some 
programmes have used qualitative urinalysis testing to promote reductions in benzoylecgonine 
metabolites to encourage initial attempts at cocaine abstinence (Petry 2001). Such programmes 
aim to achieve behavioural change amongst “hard-to-treat” patients by offering incentives 
based on goals that are within the reach of each individual (Meredith et al. 2014).12 In addition 
to targeting addictive substances themselves, some programmes also target non-drug 
behaviours as part of the patient’s overall treatment (Petry 2001; Petry and Ledgerwood 2010). 
For example, some programmes reinforce attendance at therapy sessions, submission of 
biological samples, and other goal-related behaviours13 (e.g., taking steps to find steady 
employment or dealing with legal issues). 
 
In terms of the incentive provided, CM programmes vary significantly, and it is useful to 
distinguish between the characteristics of the incentive itself and the way in which the incentive 
is delivered. The characteristics of the incentive vary in three ways.  First, the direction of the 
incentive: treatment providers can either give the subject a reward for achieving abstinence or 
impose a penalty if they fail to do so. At the midpoint between reward-based and penalty-based 
                                                
10 Biochemically verifying self-reported claims of abstinence is considered good programme design (Benowitz et 
al. 2002). However, CM programmes do not necessarily biochemically verify all patients’ self-reports: some 
programmes only verify self-reports of those individuals claiming abstinence (i.e., those individuals who may be 
eligible for the abstinence-contingent reward), while others verify self-reports among a random sample of those 
claiming abstinence (Cahill et al. 2015).  
11 Behaviour analytic theory suggests that CM programmes targeting multiple drugs may require incentives of 
significant magnitudes to be effective (Meredith et al. 2014). Specifically, remaining abstinent from multiple 
drugs simultaneously requires a considerable response effort (i.e., the difficulty associated with engaging in the 
target behaviour) from the subject and abstinence-contingent incentives therefore need to compete with the 
reinforcing effects of multiple drugs. Research suggests that targeting one drug at a time may be a more effective 
way to target polydrug abuse: subjects who achieve abstinence from a single drug may then be motivated to 
abstain from the primary as well as secondary drug(s) (Petry 2001). Most CM studies that target abstinence from 
a single drug find reductions in other drug use as well (Petry 2001).   
12. These programmes, as well as those that target one drug at a time rather than multiple drugs simultaneously 
(see Footnote 9), reinforce successive approximations: they reinforce behavioural responses that bring the subject 
closer to the desired result (i.e., each small step along the way is reinforced to establish a pattern of drug 
abstinence) (Petry 2001).  
13 Targeting and reinforcing non-drug behaviours, in addition to targeting the addictive substance itself, typically 
occurs in CM programmes treating patients addicted to “hard-core” drugs (e.g., cocaine, heroin) that are often 
associated with drug-related issues.  
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interventions are deposit-refund interventions: subjects deposit their own money14 into an 
account and the money is either recovered or forfeited depending on whether the subject 
remained abstinent or not. Second, the type of incentive provided varies. A number of different 
financial incentives have been provided in CM programmes, including: cash payments, 
vouchers exchangeable for goods15, salary bonuses, and other items (e.g., take-home doses of 
methadone) (Cahill et al. 2015; Prendergast et al. 2006). While this research focuses on 
financial or material incentives, it is worth noting that numerous other non-monetary incentives 
(e.g., clinic privileges, more flexible work schedules) have been used in CM interventions 
(Meredith et al. 2014; Petry 2001; Petry and Ledgerwood 2010). While the use of non-
monetary rewards reduces programme costs, it may not bring about the desired behavioural 
change: the subject may not have a preference for the non-monetary reward and, even if they 
do, the reward may lose its effectiveness as the subject becomes satiated by its repeated 
delivery (Meredith et al. 2014). Finally, the magnitude of the incentives (or total value of 
abstinence-contingent rewards available to the subject over the duration of the intervention) 
varies considerably across CM interventions, ranging from $100 (Volpp et al. 2006) to $800 
(Halpern et al. 2015) 
 
With regard to incentive delivery, there are three ways in which it can vary. First, incentive 
delivery can differ in terms of the immediacy of the reward in relation to the occurrence of the 
target behaviour (i.e., abstinence). A meta-analysis of CM interventions finds that incentive 
immediacy is associated with larger effect sizes (Prendergast et al. 2006).16 Second, the 
frequency and duration of incentive delivery varies: some programmes run for four weeks and 
incentives are provided daily, while others last several months and incentives are provided 
weekly. Behaviour analytic theory suggests that CM programmes targeting substance use may 
require frequent and prolonged reinforcement to establish and maintain behaviour change 
because drug abstinence is considered a “complex” behaviour which involves repeated choices 
over an extended period of time (Kane et al. 2004; Meredith et al. 2014). This contrasts to 
“simple” health-related behaviours (e.g., arriving for an HIV test or arriving for a once-off 
                                                
14 Some CM programmes conducted in clinic settings offer different refunds or rebates (Petry 2001). Some clinic-
based programmes require subjects to pay a fee upon entry into the treatment programme, which is refunded if 
the subject completes the programme and maintains abstinence. Others reduce fees for service or provide a rebate 
of the treatment costs when abstinence is achieved and maintained.  
15 As mentioned, voucher-based reinforcement therapy (VBRT) - as the procedure is often called - was popularised 
by Higgins and colleagues and remains a commonly used CM incentive.  
16 To reduce the delay between behaviour change and incentive delivery, CM interventions typically use on-site 
test kits which provide results immediately (Petry 2001). The decision regarding which test method to use does, 
however, also depend on the half-life of the drug and the cost of the test-kit (Benowitz et al. 2002; Petry 2001). 
	 -11- 
immunisation appointment) that are commonly targeted in more general incentive-based 
programmes and may require less frequent and less prolonged reinforcement.  
 
Third, the schedule according to which incentives are delivered differs markedly. The schedule 
of reinforcement can be either fixed/uniform (i.e., the incentive is the same for each biological 
sample testing negative for the target drug) or variable. There are a number of variable 
reinforcement schedules that have been used, including an escalating schedule of reinforcement 
with a reset contingency, front loading of incentives, and intermittent reinforcement. In 
programmes adopting an escalating reinforcement schedule with a reset contingency, the target 
behaviour (i.e., abstinence) is initially reinforced with small monetary incentives (Meredith et 
al. 2014). If the subject continues to remain abstinent, the incentive magnitude increases with 
each biological sample that tests negative for the target drug. If the subject lapses, the next time 
they test negative for the target drug they are reinforced with an incentive that has been reset 
to the initial, smaller amount. This reinforcement schedule interacts dynamically with the 
behaviour of the subject and aims to promote continuous abstinence (Meredith et al. 2014; 
Prendergast et al. 2006).  
 
Front-loaded incentive schedules are the opposite of an escalating reinforcement schedule; they 
provide larger incentives initially which then reduce gradually over time. This incentive 
schedule aims to establish the target behaviour initially and maintain the treatment gains by 
providing smaller incentives over time (Meredith et al. 2014). Finally, the intermittent 
reinforcement schedule, or “fishbowl” method as it is colloquially termed, was developed by 
Petry (2001) to curtail the costs of CM interventions. Compared to programmes that offer 
rewards with certainty, programmes adopting an intermittent reinforcement schedule provide 
subjects with incentives for a proportion of behaviours. Specifically, each time the subject 
achieves his/her target behaviour (e.g., submitting a negative biochemical sample) he/she earns 
the chance to draw a slip of paper from a bowl (hence the name). A certain proportion of the 
draws say “Good Job!” while the remaining draws result in winning a prize which typically 
ranges in value from $1 to $100, and the chances of winning are inversely related to the prize 




2.2.2 CM interventions targeting smoking abstinence 
 
I now turn to a discussion of the CM literature that draws on Cahill et al. (2015) and which is 
relevant to this dissertation. Specifically, I will review 21 published studies evaluating CM 
interventions offering smokers material or financial incentives for abstinence from tobacco use, 
and discuss them in relation to the features of CM interventions outlined above. All included 
studies are RCTs17 that report cessation rates and follow study participants for at least six 
months18 from the start of the intervention. The 21 studies cover 8400 individuals, with study 
sample sizes ranging from 45 (Alessi and Petry 2014) to 2538 (Halpern et al. 2015). 
 
With regard to the setting and targeted population, 15 of the studies were conducted in the 
United States, and the remaining studies were conducted in the United Kingdom (Paxton 1980, 
1981, 1983), Spain (Secades-Villa et al. 2014), the Philippines (Giné et al. 2010), and Thailand 
(White et al. 2013). Ten of the studies were conducted with individuals in clinics or health 
centres, seven in worksites (Glasgow et al. 1993; Halpern et al. 2015; Hennrikus et al. 2002; 
Jason et al. 1995; Rand et al. 1989; Volpp et al. 2009; Windsor et al. 1988), two in academic 
institutions (Ledgerwood et al. 2014; Tevyaw et al. 2009), one in an urban community (Giné 
et al. 2010), and one in villages served by community health workers (White et al. 2013).  
 
With regard to the targeted behaviour, all studies targeted abstinence from smoking. 
Abstinence has been defined in multiple ways. Hughes et al. (2003) recommends that trials 
should report prolonged abstinence (sustained abstinence after an initial grace period) and point 
prevalence abstinence (PPA) (prevalence of abstinence during a time window immediately 
preceding a meeting, commonly 7 days). All 21 included studies report either or both of these 
measures. In addition to targeting abstinence, two studies targeted smoking reductions initially 
                                                
17 While several of the studies include multiple treatment arms, this review focuses on the comparison of the 
financial/material incentive treatment and the appropriate control condition. In most cases the appropriate 
control/comparison group typically receives some form of minimal intervention because CM is predominantly 
conducted on a ‘platform’ of another treatment/support programme rather than as a stand-alone treatment 
(Prendergast et al. 2006). For example, some programmes provide information (e.g., provision of self-help/quit 
guides, information about local smoking cessation services), some provide counselling and support (e.g., cessation 
skill training, help with creating a quit plan), and some provide medication (e.g., varenicline, bupropion, and 
nicotine replacement therapies such as patches and gum) (Meredith et al. 2014; Petry 2001; Petry and Ledgerwood 
2010). 
18 The purpose of the follow-up period is to establish the rate of remission across the treatment and control groups 
and to establish whether a treatment effect remains after the contingency period is over. Follow-up sessions should 
be tied to subjects’ quit dates (Hughes et al. 2003). 
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and subsequently targeted abstinence19, and several studies also included incentives for 
participation/attendance and compliance, e.g., submitting a biological sample (Alessi and Petry 
2014; Crowley et al. 1995; Gallagher et al. 2007; Giné et al. 2010; Halpern et al. 2015; 
Hennrikus et al. 2002; Ledgerwood et al. 2014; Rand et al. 1989; Tevyaw et al. 2009; Volpp et 
al. 2006; Volpp et al. 2009). 
 
There is significant variation across studies both in terms of the characteristics of incentives 
provided and the delivery of the incentives. Regarding the incentive direction, six studies 
adopted deposit contracts20 (Giné et al. 2010; Halpern et al. 2015; Paxton 1980, 1981, 1983; 
White et al. 2013)21  and all remaining studies offered positive incentives. Regarding the type 
of incentive provided, nine studies provided cash incentives22 (Drummond et al. 2014; 
Gallagher et al. 2007; Halpern et al. 2015; Jason et al. 1995; Rand et al. 1989; Tevyaw et al. 
2009; Volpp et al. 2006; Volpp et al. 2009; Windsor et al. 1988), two studies provided prize 
draws (Alessi and Petry 2014; Ledgerwood et al. 2014), two studies provided both cash and a 
prize or cash draw (Glasgow et al. 1993; Hennrikus et al. 2002), two studies provided vouchers 
exchangeable for goods (Secades-Villa et al. 2014; Shoptaw et al. 2002), and one study 
provided lottery tickets (Crowley et al. 1995). Regarding incentive magnitude, total available 
earnings varied from $50 (Drummond et al. 2014) to $800 (Halpern et al. 2015).23  
 
Regarding the immediacy of incentive delivery, most studies offered incentives immediately, 
although Hennrikus et al. (2002) provides a cash draw every 6 months (i.e., not immediately) 
in addition to immediate cash incentives. The duration of the intervention period (i.e., the 
period over which incentives were delivered) ranged from several weeks (Alessi and Petry 
                                                
19 Tevyaw et al. (2009) offered incentives for reductions in smoking intensity in the first week of the programme 
($1 for a 25-49% reduction in the CO reading, $2 for a 50-74% reduction, and $3 for a reduction of 75% or more) 
and incentivised complete abstinence from the second week onwards. Ledgerwood et al. (2014) offered incentives 
for CO readings that had reduced by at least 3 ppm in the first week and thereafter incentivised complete 
abstinence.  
20 Halpern et al. (2015) includes two deposit-refund treatments. The first treatment provided subjects with their 
own deposited money as well as additional cash payments for abstinence. In the second treatment, subjects were 
placed into groups of six and received their own deposited money for abstinence, as well as additional cash 
payments per successful quitter in their group.  
21 While participants in Giné et al. (2010) and Paxton (1980, 1981, 1983) received their deposited cash conditional 
on abstinence, participants in Halpern et al. (2015) and White et al. (2013) received their deposited cash as well 
as bonus cash payments (i.e., they received deposit repayments as well as positive incentives).   
22 In addition to the two deposit-refund treatments, Halpern et al. (2015) includes two cash-based treatments. As 
with the deposit-refund treatments, the first treatment is individual-based and the second is group-based: the first 
provides cash rewards contingent on abstinence, while the second groups participants into teams of six and 
provides subjects with cash rewards contingent on their own abstinence plus additional cash rewards for each 
team member who is abstinent.  
23 These figures are for studies providing positive incentives and do not include deposit-refund studies.  
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2014) to a full year (Glasgow et al. 1993), and the frequency of incentive delivery varied 
significantly with some studies delivering incentives daily (Alessi and Petry 2014; Crowley et 
al. 1995; Jason et al. 1995; Ledgerwood et al. 2014; Tevyaw et al. 2009) and others providing 
incentives only at the end of the intervention period (Giné et al. 2010). Finally, studies 
employed numerous incentive schedules, including: a uniform incentive schedule (Crowley et 
al. 1995; Glasgow et al. 1993; Hennrikus et al. 2002; Jason et al. 1995; Rand et al. 1989), an 
escalating incentive schedule (Gallagher et al. 2007), an escalating incentive schedule with a 
reset contingency (Drummond et al. 2014; Secades-Villa et al. 2014; Shoptaw et al. 2002; 
Tevyaw et al. 2009), a frontloaded/tapering incentive schedule (Halpern et al. 2015), and an 
intermittent reinforcement schedule (Alessi and Petry 2014; Ledgerwood et al. 2014). With 
regard to the incentive schedules for deposit contract studies, three studies (Paxton 1980, 1981, 
1983) varied the repayment schedules (the deposits were either returned uniformly or the 
repayments thinned out) as opposed to returning deposits at a single time point, which all other 
studies did.  
 
Before discussing the results of the 21 studies, I will examine the potential sources of bias that 
may limit one’s ability to draw valid and robust causal inferences from these studies. The 
Cochrane Library has developed a taxonomy for sources of bias that may arise from design 
and implementation issues and I will use it as a framework for discussing the 21 RCTs under 
review (The Cochrane Collaboration 2008). First, selection bias refers to systematic differences 
between baseline characteristics of the groups in a study.24 Randomisation procedures can be 
used to prevent selection bias in allocating treatment to study participants. Achieving 
successful randomisation requires that there is adequate sequence generation (i.e., there is a 
specified rule for allocating treatment to participants which is based on some random process) 
and that the upcoming treatment allocation is concealed from potential participants during 
enrolment into the RCT. Cahill et al. (2015) concludes that seven studies conducted adequate 
randomisation procedures: sequence generation and allocation concealment (Drummond et al. 
2014; Halpern et al. 2015; Ledgerwood et al. 2014; Volpp et al. 2006; Volpp et al. 2009; White 
et al. 2013; Windsor et al. 1988); four studies followed adequate sequence generation 
procedures but did not achieve adequate allocation concealment (Alessi and Petry 2014; 
Gallagher et al. 2007; Secades-Villa et al. 2014; Shoptaw et al. 2002); five studies gave 
                                                
24 Selection bias in economics typically refers to the unrepresentativeness of a sample relative to the population it 
is supposed to represent. This bias can have a number of causes, including self-selection. The Cochrane Library’s 
definition is, therefore, restrictive (see Wooldridge 2010, p. 790-792).  
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insufficient detail for the integrity of the randomisation procedure to be assessed (Glasgow et 
al. 1993; Hennrikus et al. 2002; Jason et al. 1995; Rand et al. 1989; Tevyaw et al. 2009); and 
the remaining studies used inadequate randomisation procedures.  
 
Second, performance bias refers to systematic differences between groups’ outcomes that arise 
from knowledge of treatment allocation, rather than the treatment itself. After enrolment into 
the study, blinding of participants and personnel to the treatment allocation may reduce the risk 
of performance bias. Blinding personnel may help ensure that compared groups receive equal 
attention, ancillary treatment, and diagnostic investigations. Blinding of participants may 
reduce the risk of a Hawthorne, John Henry, or resentment and demoralisation effect.25  
However, because of the explicit reward mechanism in CM interventions, blinding of personnel 
is very difficult and complete blinding of subjects is not possible. In particular, while medical 
trials testing new drugs can blind personnel and subjects to treatment allocation relatively 
easily (i.e., it is impossible to distinguish between the drugs and the placebo that the treatment 
and control subjects receive, respectively), the personnel and treatment subjects in a CM 
programme know whether the abstinence-contingent incentive is being delivered.  Only four 
studies reported any attempt to blind subjects or assessors (Crowley et al. 1995; Jason et al. 
1995; Tevyaw et al. 2009; Volpp et al. 2006).  
 
Third, attrition bias refers to systematic differences in withdrawals from a study across groups. 
Cahill et al. (2015) deem eleven studies to be at low risk of attrition bias and nine studies to be 
at unclear risk. Rand et al. (1989) is rated at high risk, with significantly higher attrition in the 
treatment group, although reasons for drop-out were largely unrelated to the cessation 
intervention (e.g. heart attack, pregnancy, relocation for work). In terms of data analysis, fifteen 
studies treated drop-outs and losses to follow-up as continuing smokers, and conducted the 
analyses on an intention-to-treat basis (Alessi and Petry 2014; Crowley et al. 1995; Drummond 
et al. 2014; Gallagher et al. 2007; Giné et al. 2010; Glasgow et al. 1993; Halpern et al. 2015; 
Jason et al. 1995; Ledgerwood et al. 2014; Rand et al. 1989; Secades-Villa et al. 2014; Volpp 
et al. 2006; Volpp et al. 2009; White et al. 2013; Windsor et al. 1988). 
 
                                                
25 A Hawthorne effect is when the treatment group works harder than normal. A John Henry effect is when the 
comparison group starts competing with the treatment group. A resentment and demoralisation effect is when the 
members of the comparison group resent missing out on treatment which may lead them to behave in ways that 
worsen their outcomes (Glennerster and Takavarasha 2013).  
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There is one further issue, specific to CM studies, which could lead to bias and limit the 
reliability of results. In CM studies, there is a possibility of systematic differences in reports of 
abstinence amongst treatment and control subjects: treatment subjects may be tempted to 
misreport abstinence because of the contingent nature of the rewards. Biochemically verifying 
abstinence is important for mitigating such deception.26 All included studies used some form 
of biochemical validation of abstinence, either by testing breath samples for carbon monoxide 
(CO) levels (Crowley et al. 1995; Rand et al. 1989), or by testing cotinine (a metabolite of 
nicotine) levels in blood, saliva, or urine (Giné et al. 2010; Halpern et al. 2015; Hennrikus et 
al. 2002; Paxton 1980, 1981, 1983; Volpp et al. 2006; Volpp et al. 2009; White et al. 2013; 
Windsor et al. 1988), or both (Alessi and Petry 2014; Drummond et al. 2014; Gallagher et al. 
2007; Glasgow et al. 1993; Jason et al. 1995; Ledgerwood et al. 2014; Secades-Villa et al. 
2014; Shoptaw et al. 2002; Tevyaw et al. 2009). Studies either tested individuals to validate 
reports of abstinence, tested a random sample of quitters, or tested all participants irrespective 
of their reported abstinence/failed abstinence. Of the 9 studies that reported disparities between 
self-reported abstinence and biochemically verified abstinence, five studies reported a good 
correspondence (Jason et al. 1995; Paxton 1980, 1981, 1983; Windsor et al. 1988) and four 
studies reported significant disparities (Crowley et al. 1995; Gallagher et al. 2007; Glasgow et 
al. 1993; Hennrikus et al. 2002).27  
 
These issues notwithstanding, the 21 studies included in this review point to some noteworthy 
findings. Cahill et al. (2015), who reanalyse the 21 studies’ data collectively, report that the 
cessation rates at the six-month follow-up demonstrate an unequivocal benefit for the incentive 
groups, with an adjusted odds ratio (OR) of 1.72 (95% confidence interval (CI) 1.43 to 2.08; 
                                                
26 A related issue is that potential participants may be tempted to misreport their smoking status to gain entry into 
the CM programme. Biochemical verification at baseline ensures that non-smokers do not gain entry into the 
programme. Nine studies took measures to verify smoking status at baseline (Crowley et al. 1995; Gallagher et 
al. 2007; Halpern et al. 2015; Ledgerwood et al. 2014; Rand et al. 1989; Secades-Villa et al. 2014; Shoptaw et al. 
2002; Tevyaw et al. 2009; Windsor et al. 1988). Cahill et al. (2015) argue that in those studies requiring subjects 
to submit baseline samples, 6% returned negative samples and 14% did not return a sample, suggesting that up to 
20% of participants trying to enrol may have been non-smokers. This points to the importance of biochemically 
verifying subjects’ smoking status before entry into a CM intervention. 
27 The Cochrane Library (2008) identifies two further sources of bias: detection bias and reporting bias. Detection 
bias refers to systematic differences between groups in how outcomes are determined. Blinding personnel who 
are assessing outcomes may reduce the risk that knowledge of treatment allocation, rather than treatment itself, 
affects outcome measurement. Blinding outcome assessors is particularly important in studies measuring 
subjective outcomes (e.g., the degree of postoperative pain). Outcomes in CM interventions are typically objective 
(e.g.., biochemically verified abstinence) and so blinding of personnel – which, as mentioned, is difficult in CM 
studies – is not as critical. Reporting bias refers to systematic differences between reported and unreported 
findings. Within published work this is the tendency to report statistically significant rather than non-significant 
results. This issue is germane to all published work.  
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6945 participants). The cessation rate at longest follow-up for each study is slightly lower, with 
an adjusted OR of 1.42 (95% CI 1.19 to 1.69; 7715 participants). However, only three trials 
find a significant effect of incentives on smoking abstinence at their longest follow-up, and two 
of these studies provided the most substantial cash payments (Halpern et al. 2015; Volpp et al. 
2009; White et al. 2013).28 The overall picture that emerges from the remaining studies is that 
incentives boost cessation rates while they are in place, but cessation rates often decline in the 
long term unless the incentives are substantial during the intervention.29  
 
Despite the evidence suggesting that CM smoking cessation interventions are efficacious, the 
cost, complexity, and staff burden of CM interventions act as a barrier to their widespread 
adoption (Secades-Villa et al., 2014). As a response to this issue, this dissertation sets out to 
test whether a low-cost, low-intensity CM intervention can prove to be an effective form of 
treatment for tobacco addiction in a student population. The programme provides relatively 
modest abstinence-contingent cash rewards and has a relatively low staff burden. In addition, 
student smokers are the ideal sample to target for a number of reasons: they are easy to recruit 
and track; their lifetime exposure to cigarettes and their smoking intensity tend to be low 
compared to older smokers so they may be more susceptible to an intervention (Mayhew et al. 
2000); their relatively low incomes mean that the rewards may be more salient; and, if the 
programme is successful at getting them to quit, the personal and societal benefits are large and 
continue to accrue over time.  
 
In this dissertation, I focus on two questions: Does a low-cost, low-intensity CM intervention 
increase smoking cessation rates and, if not, does it decrease the smoking intensity of non-
abstainers? I outline the details of the study design in Section 3 below.  
 
  
                                                
28 Halpern et al. (2015) provides $800 for sustained abstinence at six months and Volpp et al. (2009) provide 
$750. The third study, White et al. (2013), is a deposit contract intervention.  
29 Two additional findings are worth noting. First, Cahill et al. (2015) compare the impact of guaranteed rewards 
(i.e., vouchers or cash) versus uncertain rewards (i.e., lotteries or prize draws) and find that the level of certainty 
of receiving a reward has little impact on the success of the intervention. Second, Cahill et al. (2015) compare 
deposit-refund and reward-based programmes. They find that deposit-refund trials may be prone to relatively low 
uptake rates compared to reward-based programmes, but that those who do sign up for deposit-refund trials 
achieve higher rates compared to reward-based studies.  
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3. DESIGN AND METHODS 
 
The CM smoking cessation programme consisted of a recruitment period, a 6-week 
intervention period, and a 6-month follow-up period, and was designed to fit within the 
university academic calendar. Figure 1 provides an overview of the study. The recruitment 
period included a screening session; the intervention period included a baseline session (after 
which the subjects had one week to quit smoking; their quit window) and four programme 
sessions; and the follow-up period included two sessions, 3 months and 6 months after the 
subject’s quit date.30 In terms of the study’s treatment arms, subjects in the control group were 
given an aid-to-quit document in the baseline session and had their quit attempt monitored in 
the programme and follow-up sessions. Subjects in the treatment group were, additionally, 
given abstinence-contingent incentives in the programme sessions.31 I outline the details of the 
study design and methodology below. 
 
 
Figure 1: Study Overview 
 
3.1 Participants and setting  
 
The study was conducted at UCT. Participants (N = 87) were treatment-seeking student 
smokers. Inclusion criteria were: the student was at least 18 years old; had smoked at least 100 
cigarettes in his/her life; had smoked in the last 10 hours; smoked at least 5 cigarettes a day; 
reported an interest in quitting smoking and taking part in a smoking cessation programme; 
                                                
30 The quit date was the last day that the subject could smoke.  
31 As mentioned, CM is predominantly conducted on a ‘platform’ of another treatment/cessation support 
programme rather than as a stand-alone treatment (Prendergast et al. 2006). In our study, control subjects received 
an aid-to-quit document and were monitored during the intervention and follow-up phases of the study. In addition 
to the “care” that control subjects received, treatment subjects received abstinence-contingent rewards. Any 
treatment effect would therefore suggest that the abstinence-contingent rewards given to treatment subjects is 
effective over and above the “care” (information and monitoring) that control subjects receive.  
RECRUITMENT PERIOD 
Quit Window
INTERVENTION PERIOD FOLLOW-UP PERIOD 
	 -19- 
and had a carbon monoxide (CO) in expired air reading of at least 8 parts per million (ppm).32 
Figure 2 shows the flow of participants through the recruitment, intervention, and follow-up 
phases of the study. 
 
 
Figure 2: The flow of participants from the point of initial contact through to data analysis  
 
  
                                                
32 We measured carbon monoxide (CO) levels in expired air using a Micro+ Smokerlyzer® monitor (Bedfont 
Scientific Ltd.). The sensitivity and specificity of CO measurements are both around 90% (Benowitz et al. 2002). 
The sensitivity is limited by the rapid elimination of CO: with sedentary activity, the half-life of CO is 
approximately 2 – 3 hours and, for the average smoker, CO levels are no different than those of a non-smoker 
after 24 hours of not smoking. Specificity is limited by endogenous and environmental sources of CO. Expired 
air CO measurements have been used by researchers and clinicians for decades to biochemically verify self-
reported abstinence from smoking, and the Smokerlyzer brand of monitor has been used throughout the world in 
clinical research, tobacco treatment, and tobacco prevention education since the early 1980s (Benowitz et al. 
2002).  
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Treatment (Aid-to-quit, Monitoring & CM)
(n = 52)
Control (Aid-to-quit & Monitoring)
(n = 53)
Lost to 3-month follow-up
(n = 9 unable to locate)
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3.2.1 Recruitment and screening 
 
After receiving ethics approval33 to conduct the study and permission to access students, 
potential participants were recruited via an email sent to all students through UCT’s central 
mailing list. The email provided an outline of the research study, and specified the expected 
time burden and earnings. Interested students were asked to complete a short online 
questionnaire that included 13 questions on demographics, smoking patterns, and whether the 
potential participant had an interest in quitting smoking and taking part in smoking cessation 
programme (i.e., whether they were treatment seeking). This information was used to screen 
out students who were ineligible based on self-reported information.34 Over 700 students 
showed an interest in taking part in the study and 294 students were eligible based on their self-
reported information (see Figure 2). 
 
Subjects deemed eligible based on self-reported information were invited to sign up for a 
screening session, via an announcement sent through the university’s virtual learning 
environment (VLE). The announcement explained what the screening session would entail, 
provided further details on the study, and asked subjects to sign up for the screening session. 
Of the 294 students who were contacted, 169 students signed up for and attended a screening 
session (see Figure 2). 
 
The screening sessions ran on week days from 19 - 26 June 2017 in an office at UCT.35 
Screening sessions were 15-minute, one-on-one sessions with a research assistant (RA)36 and 
students were paid a R50 show-up fee. An email and two SMS-reminders were sent to students 
to remind them of their session.37 Following written informed consent, the RA verbally ran 
                                                
33 Ethics approval reference: REC/2017/05/002  
34 This meant that a smaller, more refined sample of students attended the screening sessions, thereby reducing 
both the time taken to screen potential participants and the cost of the study. 
35 To provide students with flexibility and to ensure that they were not prevented from attending due to clashes 
with their lectures, the screening sessions ran from 09:00-12:00 and 13:00-17:00 every day. The same approach 
was adopted for the programme and follow-up sessions.   
36 We limited the number of people running the screening sessions (myself and one other RA) to ensure 
consistency across sessions. The same approach was adopted for the programme sessions.   
37 The email was sent the day before the student’s session, and the SMS-reminders were sent at 17:00 the day 
before the session and at 08:00 on the day of the session. The same applies to the reminders sent before the 
baseline, programme, and follow-up sessions.   
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through the same questionnaire that students had completed online and took a CO reading to 
determine potential participants’ smoking status.38 Before leaving, subjects were paid the R50 
show-up fee and were told that they would be contacted if they were eligible to take part in the 
study. Of the 169 students who attended the screening sessions, 119 students were eligible (see 
Figure 2), based on the criteria outlined in Section 3.1. 
 
Eligible students were invited to sign up for the baseline session, via an announcement sent 
through the university’s VLE. The announcement informed students that they were eligible to 
take part in the study, repeated the information about what the study would entail, and asked 
students to sign up for the baseline session. The baseline session marked the start of the 
smoking cessation programme and sign-up for it was, therefore, sign-up for the programme 
itself. Of the 119 eligible students that were contacted, 105 students signed up for the baseline 




After subjects had signed up for the baseline session39, randomisation to either treatment or 
control occurred using stratified random assignment (see Glennerster and Takavarasha 2013, 
p.153-158), where the stratification variables were gender, race, and CO reading. The 105 
subjects were split between the treatment and control groups (n =52 and n = 53 for treatment 
and control, respectively).  
 
  
                                                
38 As discussed, findings from previous studies point to the importance of biochemically verifying subjects’ 
smoking status before entry into a CM intervention because non-smokers may try to enrol. CO readings were also 
taken during the programme to verify abstinence (see discussion below). 
39 Randomisation happened after sign-up for the baseline session but before the baseline session itself for three 
reasons. First, because sign-up for the baseline session was sign-up for the programme itself, those subjects who 
signed up for the baseline session needed to be randomised into either the treatment or control group. Second, 
randomisation in the baseline session itself was not possible because, due to our relatively small sample size, we 
needed to stratify; an impossibility if we randomised in the session itself. Third, while it would have been 
preferable to randomise after the baseline session (this would have allowed for stratification on the information 
collected in the baseline session, particularly updated CO readings), treatment subjects needed to be informed, 
during the baseline session, that they would receive abstinence-contingent rewards in the programme sessions; 
treatment subjects needed this information for it to affect their quit attempt. The decision about when to randomise 
– in particular, the decision to randomise after baseline sign-up – meant that the baseline sessions were run with 
treatment and control subjects together. Furthermore, it meant that subjects randomised into the treatment or 
control group could “drop out” before the baseline session/start of the programme. Figure 2 indicates that 18 
subjects dropped out before the baseline session – see Section 5.4.2 for a discussion of this issue.  
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3.2.3 Baseline  
 
The baseline sessions ran from 14 - 18 August 2017 in a computer lab at UCT and involved 
both a group and individual component. It was the longest of all the study sessions, lasting 
approximately two hours, on average. An email and two SMS-reminders were sent to subjects 
to remind them of their session. Seven sessions40 took place in total and the mean group size 
was 13 participants. Each subject received a R50 show-up fee and had the opportunity to make 
additional earnings in the two decision-making tasks (see below); subjects earned R604, on 
average, during the session. I assumed the role of presenter for every session, to ensure 
consistency across the sessions, and three RAs were employed to help administer subject 
payments, answer questions, and take CO readings.  
 
Upon arrival at the lab, subjects were randomly allocated to computer terminals and the group 
component of the baseline session commenced. Following written informed consent, for both 
the baseline session itself and the remaining study sessions, I delivered a presentation 
explaining, in detail, what the smoking cessation programme would entail. Subjects then signed 
up for the programme sessions through the university’s VLE. Following sign-up, subjects 
completed two decision-making tasks designed to elicit their risk and time preferences. 
Subjects received both written and audio-visual instructions for the tasks and the order of the 
tasks was counter-balanced across sessions so subjects either performed the risk or time 
preference task first.41  
 
The risk preference task presented subjects with choices between two lotteries; these lotteries 
were displayed as pie charts with accompanying text that listed the prizes and their 
probabilities.42 The task used prize magnitudes between R0 and R1320 and probabilities which 
varied in increments of 0.05 between 0 and 1. Subjects made 90 choices in this task. It took 
subjects 20 minutes, on average, to complete the task and subjects earned R226, on average. 
The time preference task presented subjects with choices between smaller, sooner (SS) and 
                                                
40 To provide students with flexibility and to ensure that they were not prevented from attending due to clashes 
with their lectures, the seven baseline sessions were spread out over the week.  
41 The task order was counter-balanced to avoid potential order effects, where behaviour in a task may be 
influenced by the prior treatment/task (Friedman and Sunder 1994). Hofmeyr (2015) found evidence of order 
effects in similar tasks run on the same population.  
42 As mentioned in Section 2.2, a number of CM studies offer uncertain rewards (e.g., prize or cash draws, where 
not all draws result in the subject receiving a prize). While this approach has been used to reduce study costs, we 
could not provide uncertain rewards as it would have interacted with the risk preference information we collected. 
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larger, later (LL) monetary rewards. The task employed two smaller, sooner (SS) rewards 
(R250 and R400) and nominal annual interest rates that varied between 0% and 250% to 
determine the larger, later (LL) rewards. Subjects made 60 choices in this task. It took 10 
minutes, on average, for subjects to complete the task and subjects earned R331, on average.43  
 
Upon completion of the tasks, subjects were instructed to complete the baseline questionnaire. 
The questionnaire included: 10 questions on socioeconomic and demographic information; the 
Barratt Impulsiveness Scale (Patton et al. 1995); four validated psychological screens focussing 
on depression (the Beck Depression Inventory-II, Beck et al. 1996), anxiety (the Beck Anxiety 
Inventory, Beck et al. 1988), drinking behaviour  (WHO Alcohol Use Disorders Identification 
Test, WHO 2001), and gambling behaviour (The Problem Gambling Severity Index, Ferris and 
Wynne 2001); and the tobacco and nicotine use module from the National Epidemiological 
Survey on Alcohol and Related Conditions-III (NESARC-III, Grant et al. 2014).44 In addition 
to the NESARC-III tobacco and nicotine use module, the questionnaire included additional 
modules and questions related to cigarette smoking: it administered the Fagerstrom Test for 
Cigarette Dependence (FTCD, Fagerström 2012; Heatherton et al. 1991), the Smoking 
Abstinence Self-Efficacy Questionnaire (SASEQ, Spek et al. 2013), the Minnesota Tobacco 
Withdrawal Scale-Revised (MTWS-R, Etter and Hughes 2006), and the Reasons for Quitting 
Questionnaire (RFQ, Curry et al. 1990). Additionally, it included questions about past quit 
attempts (Ontario Tobacco Research Unit 2015), motivation to quit (National Centre for 
Smoking Cessation and Training 2017), attitudes towards UCT’s new smoking policy, and 
environmental factors that may affect a quit attempt, e.g., friends, family, or co-inhabitants 
who smoke (Ontario Tobacco Research Unit 2015).  
 
Following completion of the questionnaire, subjects were taken one at a time to the individual 
component of the baseline session that took place in private rooms in the computer lab. RAs 
provided subjects with a summarised explanation of the cessation programme and took their 
CO reading. Subjects were given their cash earnings45, an aid-to-quit document46, and a printed 
                                                
43 The risk and time preference tasks will not be discussed in any further detail because they are not the focus of 
this dissertation. 
44 These modules have been widely used to measure impulsivity, depression, anxiety, and alcohol and gambling 
disorders, respectively. These screens will not be discussed in any further detail because they are not the focus of 
this dissertation. 
45 Some subjects made additional earnings in the time preference task that were paid to them at a future date. RAs 
collected subjects’ banking details and this money was paid to the subjects via electronic transfer on the relevant 
date. 
46 The aid-to-quit document was Helpguide.com’s (2017) online guide for helping people quit smoking. 
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copy of the cessation programme explanation (with their programme session dates filled in). 
Subjects were then free to leave. Following the baseline session, subjects had one week to quit 
smoking.  
 
In addition, after taking treatment subjects’ CO readings, RAs informed treatment subjects that 
they had been randomly selected to earn abstinence-contingent incentives during the 
programme sessions. Given that baseline sessions were run with treatment and control subjects 
together (see Footnote 39), treatment subjects were informed about the abstinence-contingent 
rewards (i.e., provided with treatment information) in the individual component of the baseline 
sessions. Up until this point the treatment allocation was concealed from subjects (i.e., subjects 
were not informed about treatment before sign-up for the programme), because, as mentioned, 
allocation concealment - along with an adequate sequence generation procedure  – helps avoid 
a selection bias issue. However, the explicit reward mechanism in CM interventions makes 
complete blinding of subjects impossible and creates a potential for performance bias. To 
minimise the possibility of performance bias, we chose to reveal treatment information to 
treatment subjects but not to control subjects. This design reduces the possibility of a John 
Henry effect, and a resentment and demoralisation effect. While there is certainly the 
possibility for a Hawthorn effect, Harrison and List (2004) question the extent to which the 
Hawthorn effect affects behaviour.  
 
An additional benefit of informing treatment subjects about treatment in the individual 
component of the baseline session was that we could ensure comprehension of the abstinence-
continent rewards, a necessity for the effectiveness of a CM programme (Meredith et al. 2014). 
In particular, RAs explained when and under what conditions the abstinence-contingent 
rewards would be paid, and subjects were able to ask any questions they may have had.  In 
addition, when providing treatment subjects with treatment information, it was emphasised that 
they had been randomly selected to form part of the group that received the additional 
incentives. This was done so that if control subjects found out from treatment subjects that 
there was a group receiving additional incentives, they would know that the process by which 





3.2.4 Programme sessions  
  
The programme sessions ran from 28 August - 22 September 2017 in an office at UCT. The 
purpose of the programme sessions was to monitor subjects’ abstinence/quit attempt and to 
provide treatment subjects with abstinence-contingent incentives to positively reinforce 
abstinence from smoking. Each subject attended four weekly programme sessions, starting one 
week after their quit date. The sessions were 15-minute, one-on-one meetings with a RA. An 
email and two SMS-reminders were sent to subjects to remind them of their session. In each 
of the sessions, subjects earned a R50 show-up fee and treatment subjects earned an additional 
R150 payment if they were abstinent in the previous week (see below). In each of the four 
programme sessions, a RA ran through a short questionnaire with the subject, took their CO 
reading47, and paid the subject his/her earnings.48  
 
The programme session questionnaires employed the timeline followback (TLFB) method to 
determine smoking behaviour in the 7 days prior to the session (Robinson et al. 2014), the 
SASEQ, the MTWS-R, and the FTCD.49 TLFB is a calendar-based method used to capture 
retrospective daily substance use. The method was originally developed to obtain self-reports 
of alcohol use, but has been extended to other addictive behaviours (i.e., cigarette, marijuana, 
and other drug use). The method involves asking subjects to retrospectively estimate, and fill 
in on a calendar, their substance use in the period (between 7 days to 2 years) prior to the 
interview date. The method can be administered by an interviewer, by a computer, or by the 
subject him/herself. Psychometric evaluations of the method indicate that TLFB can be used 
to collect psychometrically sound information about substance use in treatment-seeking and 
nontreatment-seeking populations for periods ranging up to 12 months prior to the interview 
(Robinson et al. 2014). In the current study, TLFB was administered by a RA to capture 
subjects’ self-reported cigarette50 use in the 7 days prior to each programme session. Each 
                                                
47 In contrast to a number of studies in the literature, we took the CO readings of all subjects and not just those 
who reported abstinence.  
48 Data from the questionnaire and CO reading were captured in the Qualtrics survey framework, and the script 
read by the RA when paying the subject was presented in the same framework – see Section 3.2.4.1. 
49 The questionnaire in the fourth and final programme session included several additional questions. The 
questionnaire asked the subject whether they knew other students taking part in the study, how many other students 
they knew who were taking part, and the names of those students. Additionally, the questionnaire asked the subject 
to list the reasons for why they thought they had remained, or failed to remain, abstinent, and what approach they 
had adopted to help them with their quit attempt. Treatment subjects were asked whether, and why, they thought 
the weekly R150 abstinence-contingent payments had or had not helped with their quit attempt. 
50 The TLFB method was also used to capture whether subjects used cigarette-substitutes to aid them with their 
quit attempt. Subjects were asked whether they had used nicotine replacement therapy (NRT) or an e-cigarette in 
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subject was allocated a printed calendar (see Figure 3) that was filled in in each programme 
session.51 The calendar was filled in starting with the day before the session date and the RA 
tracked backwards to cover the full 7-day retrospective period. For each day, the RA asked the 
subject if they had remained abstinent from smoking and, if they had not remained abstinent, 
how much they had smoked on that day.52, The TLFB data can be used to derive the 7-day PPA 
abstinence measure, and to capture daily smoking intensity over the four-week period in which 




Figure 3: Timeline Followback Calendar 
Note: This is an example calendar for a subject who attended a baseline session (session 1 from the perspective 
of the subject) on 14 August, attended programme sessions (session 2-5 from the perspective of the subject) on 
Mondays during the 4-week period over which the sessions were run, and attended the first follow-up session 
(session 6 from the perspective of the subject) on 6 November. 
 
                                                
the 7 days prior to the programme session. Quantitative estimates of these substitutes are not meaningful which 
is why we only asked subjects whether or not they had used NRT or e-cigarettes, rather than how much they had 
used (Sobell et al. 1996). 
51 A printed calendar was used because it was easier for the RA to fill in with the subject. The RA captured the 
data in Qualtrics at the end of each subject’s session. 
52 Subjects were told that smoking a puff of a cigarette would be captured as having smoked one cigarette. They 
were also told that, if they were struggling to recall exactly how many cigarettes they had smoked, they should 
provide their best estimate of their cigarette use on each day.  
 MON TUES WED THURS FRI SAT SUN 





7 VAC 8 VAC 9 VAC 10 VAC 11 VAC 12 VAC 13 VAC 
14  SESSION 1 15  16 17 18 19 20 
21 QUIT DATE 22 23 24 25 26 27 





4 SESSION 3 5 6 7 8 9 10 
11 SESSION 4 12 13 14 15 16 17 
18 SESSION 5 19 20 21 22 23 VAC 24 VAC 





2 3 4 5 6 7 8 
9 10 11 12 13 14 15 
16 17 18 19 20 21 22 
23 24 25 26 27 28 29 





6 SESSION 6 7 8 9 10 11 CONSOLIDATION 12 CONSOLIDATION 
13 CONSOLIDATION 14 CONSOLIDATION 15 EXAMS 16 EXAMS 17 EXAMS 18 EXAMS 19 EXAMS 
20 EXAMS 21 EXAMS 22 EXAMS 23 EXAMS 24 EXAMS 25 EXAMS 26 EXAMS 





4 VAC 5 VAC 6 VAC 7 VAC 8 VAC 9 VAC 10 VAC 
11 VAC 12 VAC 13 VAC 14 VAC 15 VAC 16 VAC 17 VAC 
18 VAC 19 VAC 20 VAC 21 VAC 22 VAC 23 VAC 24 VAC 




After completing the questionnaire, the RA took the subject’s CO reading.53 The subject was 
considered abstinent if they reported, in the TLFB section of the questionnaire, being abstinent 
in the previous 7 days and if they had a CO reading of 6 ppm or less54; both conditions had to 
be satisfied for the subject to be classified as abstinent. In what follows, a subject is only 
considered abstinent if they satisfy these two conditions. Every subject received a R50 show-
up fee. Treatment subjects who were abstinent were paid an additional R15055; this constitutes 
the positive reinforcement that is CM.56 To minimise the risk of attrition, each subject was paid 
a R200 attendance reward in the final programme session if he/she had attended all four 
programme sessions, irrespective of whether he/she was abstinent.57  
 
3.2.4.1 Paying the subject 
 
For a CM programme to bring about its targeted behavioural change, it should not only be 
designed using the basic principles of CM, outlined in Section 2.2, but it also needs to be 
administered correctly (Ledgerwood and Petry 2010; Petry and Ledgerwood 2010). To this 
end, I developed a script for the RAs to read when giving subjects their earnings in each of the 
programme sessions. The script was drafted to promote abstinence from smoking and 
attendance at the programme sessions (i.e., there were two targeted behaviours).58  
 
I developed the script using the principles outlined in the Contingency Management 
Competence Scale for Reinforcing Abstinence (CMCS, Ledgerwood and Petry 2010) and the 
Contingency Management Competence Scale for Reinforcing Attendance (CMCS-RA, Petry 
                                                
53 Due to the short half-life of carbon monoxide, the CO readings taken during the four programme sessions do 
not biochemically verify abstinence for the full 7-day retrospective period on which the subjects reported in the 
TLFB section of the questionnaire. Instead, the CO readings were used to deter deception and to establish whether 
the subject had smoked in the previous day/24 hours.  
54 6 ppm or less is considered a conservative cut-off point between smokers and non-smokers (Benowitz et al. 
2002). 
55 The abstinence-contingent R150 incentives paid in the weekly programme session were awarded independently 
of abstinence in previous programme sessions. 
56 As mentioned in Section 2.2, the incentive schedule of CM programmes varies. This study adopts a uniform 
incentive distribution; the abstinence-contingent reward was R150 in each of the four programme sessions. The 
research team on this study have proposed a larger and more complex study for which the current study will serve 
as a pilot. Amongst other things, the proposed intervention will adopt different incentive schedules and, as such, 
the current study, with its uniform incentive distribution, serves as a starting point for the proposed study.  
57 Subjects were reminded about the attendance reward in each of the programme sessions to ensure that the 
reward was salient. 
58 As mentioned in Section 2.2, in addition to addictive substance use itself, CM has been used to target a number 
of other related behaviours, including attendance at sessions. While this dissertation focuses on a CM programme 
that provides financial incentives to positively reinforce abstinence from smoking, we decided that it was also 
important to reinforce attendance at the programme and follow-up sessions to minimise the risk of attrition.  
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and Ledgerwood 2010). CMCS and CMCS-RA are 12- and 9-item rating scales used to 
evaluate whether therapists/interviewers are implementing a CM intervention correctly. Using 
this framework, I developed scripts for treatment and control59 subjects that varied depending 
on whether the subject was abstinent in the current programme session, whether they had 
attended previous programme sessions, and whether they had been abstinent in previous 
programme sessions – see Table A in the Appendix. Therefore, behaviour (i.e., attendance and 
abstinence) in both the current and past sessions determined the script that was read, and the 
script became increasingly complicated in each subsequent programme session.60 
 
CMCS and CMCS-RA emphasise the importance of discussing certain points when paying the 
subject the incentive designed to positively reinforce the targeted behaviour (i.e., either 
attendance or abstinence). To this end, the script I developed mentioned specific points when 
discussing both abstinence and attendance. With regard to abstinence, the RA discussed 
abstinence in the current, past, and future programme sessions.  When discussing abstinence in 
the current programme session, the RA mentioned three things. First, the RA made note of 
whether the subject was abstinent and, for treatment subjects, whether the subject received the 
abstinence-contingent R150 reward. Second, the RA provided a statement of encouragement 
or support. Third, for treatment subjects, the RA made an explicit connection between the 
targeted behaviour (i.e., abstinence) and the consequence (i.e., the abstinence-contingent R150 
reward); they emphasised that the subject was receiving (was not receiving) the R150 payment 
because they were abstinent (were not abstinent) in the current programme session.  
 
When discussing abstinence in previous61 programme sessions, the RA made note of whether 
the subject had been abstinent in previous sessions62 and provided a statement of 
                                                
59 The CMCS and CMCS-RA are rating scales for CM interventions where all subjects receive treatment (i.e., 
positive reinforcement for a specified target behaviour). Because all subjects in the current study were receiving 
incentives for attendance, I drew on the CMCS-RA framework to develop scripts for both treatment and control 
subjects to discuss attendance. In contrast, only treatment subjects received incentives for abstinence. As such, I 
developed a script for treatment subjects that drew on the CMCS framework, and subsequently adapted it to create 
an equivalent script for control subjects. The scripts for treatment and control subjects were identical, therefore, 
except for the discussion points regarding abstinence: both scripts encouraged abstinence, but the script read to 
treatment subjects explicitly spoke to incentives that aimed to positively reinforce abstinence. 
60 The Qualtrics survey framework was used to avoid errors when reading the script. Specifically, the 
questionnaire and CO reading data were captured in Qualtrics and, depending on the data inputted for the subject 
(i.e., whether they were abstinent in the current programme session, and whether they had attended and were 
abstinent in previous programme sessions), the relevant script would appear for the RA to read.  
61 This was only relevant from the second programme session onwards. The same applies to the discussion on 
past attendance.  
62 For example, in the third programme session, the RA made note of whether the subject had been abstinent in 
either, or both, of the first and second programme sessions.  
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encouragement or support. When discussing abstinence in future63 programme sessions, the 
RA reminded the subject that the goal for the coming week was to remain abstinent and, for 
treatment subjects, the RA made an explicit connection between abstinence in the future 
programme session and the possibility of earning the abstinence-contingent R150 reward.64 
Finally, the RA encouraged the subject to refer to the aid-to-quit document if they were 
struggling with their quit attempt.  
 
With regard to attendance65, the RA discussed attendance in the current and future programme 
sessions. When discussing attendance in the current session, the RA mentioned three things. 
First, they noted that the subject was receiving the R50 show-up fee for attending the current 
programme session. Second, the RA made a statement of encouragement or support. Third, the 
RA made an explicit connection between the targeted behaviour (i.e., attendance) and the 
consequence (i.e., the R50 show-up fee); they emphasised that the subject was receiving the 
R50 show-up fee because they were attending the current programme session, and that the 
payment was independent of whether they were abstinent in the current programme session. 
When discussing attendance in future programme sessions, the RA reminded the subject that 
they should attend future programme sessions and that, if they did, they would receive the R50 
show-up fee; making clear the connection between attendance and the show-up fee, and 
emphasising that the show-up fee was independent of whether the subject was abstinent in the 
future programme session. Finally, the RA reminded the subject that if they attended66 all 
programme sessions, they would receive the R200 attendance bonus in the final session.67 
 
  
                                                
63 This was not relevant in the final programme session. The RA did, however, remind the subject that there were 
still two follow-up sessions and that the goal going forward was to remain abstinent. The same applies to the 
discussion on future attendance: the RA reminded the subject that there were still two follow-up sessions and that, 
if they attended, they would receive the R200 show-up fee.  
64 Treatment subjects were reminded that the weekly abstinence-contingent incentives were awarded 
independently of abstinence in previous programme sessions.  
65 Subjects were told that it was important to attend all their sessions, irrespective of whether they were abstinent 
or not. RAs told subjects that if they had failed to remain abstinent we were also interested in their smoking 
intensity.  
66 This only applied to subjects who had attended all previous programme sessions. Subjects who had missed a 
previous programme session were told that they unfortunately no longer qualified for the attendance bonus. They 
were told that they should keep attending all their programme sessions and that they would continue to receive 
the R50 show-up fee in each session.   
67 This “attendance bonus reminder” only applied to the first three programme sessions because the bonus was 
paid in the fourth and final programme session. When paying the R200 attendance bonus to the subject, the RA 
told the subject that they were receiving (were not receiving) the R200 because they had attended (had not 
attended) all of the programme sessions.  
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3.2.5 Follow-up sessions 
 
One week before each of the follow-up sessions, all subjects were invited to sign up for a 
session, via an announcement sent through the university’s VLE. The 3-month follow-up 
sessions were run from 13 – 17 November 2017 and the 6-month follow-up sessions will be 
run from 26 February – 2 March 2018.68 The purpose of the follow-up sessions is to determine 
the remission rates of treatment and control subjects after a 3-month and 6-month period. The 
sessions are 15-minute, one-on-one meetings with a RA and subjects are paid a R200 show-up 
fee.69 An email and two SMS-reminders are sent to students to remind them of their session. 
In each of the two follow-up sessions, a RA runs through a short questionnaire with the subject 
and takes his/her CO reading.  
 
The follow-up session questionnaire employs TLFB to determine smoking behaviour in the 7 
days prior to the session, the SASEQ, the MTWS-R, and the FTCD. In addition, in the 3-month 
follow-up, subjects were asked whether they had smoked since their last programme session 
and, if they had smoked, what the average number of cigarettes they had been smoking per day 
since their last programme session.70  
 
After completing the questionnaire, the RA took the subject’s CO reading and paid them the 




Subjects received a R50 show-up fee in the screening, baseline, and four programme sessions, 
and a R200 show-up fee in each of the two follow-up sessions. In the baseline sessions, subjects 
made additional earnings in the two decision-making tasks; subjects earned R557, on average, 
                                                
68 On the date of submission of this dissertation, the 6-month follow-up session is yet to be run. As such, this 
dissertation only looks at data up until the 3-month follow-up session.  
69 The show-up fee is larger than in previous sessions to minimise the risk of attrition after a prolonged period (3 
and 6 months) of not having seen the subjects. Subjects were reminded of the show-up fee in the final programme 
session, in the sign-up announcement, and in the session reminders (an email and two SMSs). 
70 The 7-day PPA and continuous abstinence measures can be derived from these data.  
71 As with the approach adopted when paying subjects in the programme sessions, the RA told the subject that the 
R200 show-up fee was for attending the session and that it was irrespective of abstinence. At the end of the 3-
month follow-up session, the RA reminded the subject about the 6-month follow-up session and about the R200 
show-up fee for that session. 
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in the tasks. In each of the four programme sessions, treatment subjects who were abstinent 
were paid the R150 abstinence-contingent incentive, over and above the R50 show-up fee.  
 
4. STATISTICAL METHODOLOGY  
 
This section outlines the statistical methodology adopted to answer the two main research 
questions: Does a low-cost, low-intensity CM intervention, conducted with a sample of 
treatment-seeking university students, increase smoking cessation rates and, if not, does it 
decrease the smoking intensity of non-abstainers? 
 
To answer the first research question, a random-effects probit model is used to examine the 
probability of abstinence. This model is appropriate because the dependent variable, 
Abstinentit, is a binary response variable. Further, the model accounts for the panel structure of 
the dataset and therefore the correlation in the standard errors over time. The regression 
specification is:  
 
Pr Abstinentit = 1 |	xit  =  Φ B1Treatmenti  +  B2x2i  + 	B3x3i  + B4x4i                      (1) 
 
where Abstinentit is a binary variable equal to one if the subject is abstinent and equal to zero 
otherwise.72 Treatmenti is a binary variable equal to one if the subject is in the treatment group 
and equal to zero if they are in the control group. Thus, B1 identifies the average difference in 
the probability of being abstinent for treatment and control subjects (i.e., the treatment effect).  
 
Vector x2 includes demographic variables and a session variable: Agei  is a continuous variable; 
Malei is a binary variable equal to one if the subject is male and equal to zero otherwise; Racei 
is a categorical variable that includes African (the base category), Coloured, Indian, and White; 
Income(ln)i is a continuous variable73; and Sessioni is a categorical variable that includes the 
baseline session (the base category), the intervention period (i.e., four programme sessions), 
and the 3-month follow-up session.  
 
                                                
72 As mentioned, two conditions have to be satisfied for the subject to be classified as abstinent: the subject has to 
report, in the TLFB section of the questionnaire, being abstinent in the past 7 days and has to have a CO reading 
of 6 ppm or less. Abstinentit is therefore a 7-day PPA measure of smoking abstinence (Hughes et al. 2003). 
73 The income(ln)i variable is constructed by taking the natural logarithm of subjects’ total income (from all 
sources) in the previous month.  
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Vector x3 includes variables related to smoking: Smoking durationi is a discrete variable 
indicating the number of years that the subject has been a daily smoker; Smoking intensityi is a 
discrete variable indicating the average number of cigarettes that the subject smokes per day; 
FTCD scorei is a discrete variable ranging from 0 – 10, where larger values indicate a greater 
level of dependence on cigarettes; MTWS-R scoreit is a discrete variable ranging from 0 – 60, 
where larger values indicate a greater level of tobacco withdrawal discomfort; and Baseline 
CO readingi is a continuous variable.  
 
Vector x4 includes variables related to quitting smoking: Quit attempt in the past 5 yearsi is a 
binary variable equal to one if the subject made a quit attempt in the past 5 years and equal to 
zero otherwise; SASEQ scorei is a discrete variable ranging from 0 – 24, where larger values 
indicate a greater level of self-efficacy regarding smoking cessation; Importance of current 
quit attempti is a categorical variable derived from a question asking the subject how 
determined they are to quit smoking on the current attempt; Determination for quit attempti is 
a categorical variable indicating how important the current quit attempt is to the subject74; RFQ 
intrinsic scorei and RFQ extrinsic scorei are discrete variables constructed from a module 
asking the subject about their reasons for quitting smoking, where larger values indicate greater 
levels of intrinsic and extrinsic motivation respectively. 75  
 
The baseline specification of Equation (1) includes Treatmenti, after which vectors x2, x3, and 
x4 are included consecutively in the analysis. Vector x2 – x4 covariates are included in the model 
to control for any differences between subjects, in order to ensure that the results of interest are 
not statistically significant merely because of correlations with omitted variables. The analysis 
of abstinence is conducted on an intention-to-treat (ITT) basis. If the subject, either treatment 
or control, did not attend their session it is assumed that they are not abstinent.76 Using this 
assumption to impute abstinence outcomes for non-attenders gives conservative absolute 
cessation rates (Cahill et al. 2015); see Section 5.4.2 for a discussion of attrition and robustness 
checks.  
 
                                                
74 The categories for Importance of current quit attempti and Determination for quit attempti are “Not at all,” 
Quite,” “Very,” and “Extremely.” 
75 With the exception of MTWS-R scoreit, all independent variables were measured at baseline. The same is true 
of the independent variables included in the random-effects negative binomial model used to analyse smoking 
intensity. MTWS-R scoreit is a time-variant variable, which was measured in each session.  
76 All Abstinentit descriptive statistics are also conducted on an ITT basis.  
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To answer the second research question (i.e., does the low-cost, low-intensity CM programme 
reduce smoking intensity amongst those subjects who failed to remain abstinent?), a random-
effects negative binomial model is used to examine the smoking intensity of those subjects who 
failed to remain abstinent. This model is appropriate because the dependent variable, Smoking 
intensityit, is a count variable. Further, the model accounts for the panel structure of the dataset 
and therefore the correlation in the standard errors over time.  
 
For the random-effects negative binomial regression of smoking intensity, let yit be the count 
dependent variable Smoking intensityit, which indicates the average number of cigarettes 
smoked per day for the ith subject in the tth session.77 We begin with the model yit | γit ~ Poisson 
(γit), where γit | δi ~ gamma (λit, δi) and λit = exp(xitB), where δi is the dispersion parameter. 
This produces the model:  
 
Pr Yit = yit | Xit, δi  = 
Γ λit + yit
Γ λit Γ yit + 1
1
1 + δi 
λit δi 
1 + δi 
yit          (2) 
 
For a random-effects negative binomial model, δi is allowed to vary randomly across subjects, 
and we assume, therefore, that 1/(1 + δi) ~ Beta(r, s). As with the random-effects probit model 
used to examine the probability of abstinence, independent variables, xit, are included 
consecutively in the random-effects negative binomial model. All independent variables are 
identical to those in the random-effects probit model, expect that Smoking intensityi is not 
included in vector x2, for obvious reasons. 
 
Together Equation (1) and Equation (2) constitute a hurdle model.  A hurdle-model is a two-
part model which specifies one data generating process (DGP) for the “participation” decision 
(y = 0 versus y > 0) and another DGP for the “amount” decision (the value of y over positive 
values). The logic behind a hurdle model is that the limit outcome (y = 0) represents a separate 
and distinct process to the non-limit outcomes (y > 0) and this limit outcome hurdle must be 
jumped or surpassed before one observes non-limit responses. In the context of the decision to 
smoke, the limit outcome (i.e., zero cigarettes smoked per day) represents the decision to not 
smoke. The non-limit outcomes (i.e., a positive number of cigarettes smoked per day), by 
contrast, represent smoking intensity, where smoking intensity is only observed for those 
                                                
77 In contrast to Smoking intensityi which is a baseline measure of smoking intensity, Smoking intensityit is a time-
variant variable constructed from TLFB data on subjects’ smoking intensity in the 7 days prior to the programme 
and follow-up sessions. 
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individuals who decide to smoke, those individuals who have jumped the hurdle. It seems 
natural then to model the limit and non-limit outcomes as the result of separate and distinct 
underlying processes.78 This is clearly important if one suspects that certain covariates may 
have opposite effects on these two decisions. In this dissertation, Equation (1) models the 
participation decision (i.e., the decision to smoke or not), and Equation (2) models the amount 




This section discusses the results of the study. Section 5.1 presents summary statistics and 
investigates whether baseline balance holds across treatment and control groups. Section 5.2 
and Section 5.3 report the results of analyses of smoking abstinence and smoking intensity, 
respectively. Section 5.4 discusses potential sources of bias and relevant robustness checks. 
Section 5.5 presents qualitative results based on questions asking subjects about their quit 
attempt. 
 
5.1 Baseline summary statistics  
 
Table I provides baseline summary statistics of the 87 subjects who took part in the study. 
Statistics for the combined, control, and treatment groups are provided, along with the results 
of tests indicating whether there is a significant difference in the observable baseline 




                                                
78 A defining characteristic of a hurdle model is the conditional independence assumption: the process which 
determines whether the independent variable y is zero or strictly positive and the process which determines the 
value of y, if it is non-zero, are independent conditional on the observable explanatory variables. It is this 
assumption that allows one to model the two DGPs separately. See Wooldridge (2010) for details. 
79 In the context of a smoking cessation programme, it is intuitive to think of the participation decision as one 
where the subject is deciding whether to be abstinent from smoking or not. As such, the dependent variable in 
Equation (1) is Abstinent which is equal to one if the subject is abstinent and equal to zero if the subject is not 
abstinent. Importantly, this approach is equivalent to a model which thinks of the participation decision as one 
where the subject is deciding to smoke or not; the dependent variable would be Smoke which is equal to one if the 
subject smokes and equal to zero if the subject does not smoke. The coefficient results would be economically 




Variable Combined Control  Treatment Significant difference?1 
Demographics     
Age  21.632 22.085 21.100 0.269 
 (2.985) (3.741) (1.614)  
Male2 0.779 0.761 0.800 0.663 
Population group2     
Black/African 28.740 27.660 30.000 0.945 
Coloured 28.740 27.660 30.000  
Indian  19.540 19.150 20.000  
White 22.990 25.530 20.000  
Income  2970.000 3376.667 2500.769 0.252 
 (2216.077) (2603.071) (1568.11)  
Cigarette smoking     
Smoking duration 3.376 3.891 2.769 0.077 
 (2.610) (2.917) (2.287)  
Smoking intensity 9.857 9.889 9.821 0.756 
 (5.895) (5.180) (6.696)  
FTCD score 3.459 3.413 3.513 0.816 
 (1.842) (1.784) (1.931)  
MTWS-R score 17.233 17.213 17.256 0.699 
 (9.969) (10.936) (8.804)  
CO reading (ppm)2 11.149 10.596 11.800 0.952 
 (9.449) (5.508) (12.662)  
Quitting smoking     
Quit attempt in past 5 years 0.659 0.739 0.564 0.090 
SASEQ score 11.310 11.447 11.150 0.791 
 (5.593) (5.559) (5.700)  
Importance of current quit 2.929 3.000 2.846 0.724 
 (0.897) (0.919) (0.875)  
Determination for current 
quit 3.047 3.152 2.923 0.285 
 (0.770) (0.788) (0.739)  
RFQ intrinsic score 4.555 4.852 4.205 0.097 
 (1.749) (1.500) (1.964)  
RFQ extrinsic score 2.444 2.557 2.310 0.279 
 (1.261) (1.254) (1.271)  
Notes: FTCD = Fagerstrom Test for Cigarette Dependence; MTWS = Minnesota Nicotine Withdrawal Scale; SASEQ = 
Smoking Abstinent Self-efficacy Questionnaire Score 
1 Mann-Whitney test for continuous variables and 𝜒2 test for categorical variables 
2 Stratification variable      
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In the combined sample, approximately 78% of subjects are male; and 29% are African, 29% 
are Coloured, 20% are Indian, and 23% are White. Subjects are approximately 22 years old 
and have a monthly income of R2970, on average. Focussing on variables related to cigarette 
smoking (x3 variables), subjects had been smoking for approximately 3 years, had a smoking 
intensity of approximately 10 cigarettes per day, had a FTCD score of 3, had a MTWS-R score 
of 17, and had a CO reading of 11 ppm, on average. With regard to variables related to quitting 
smoking (x4 variables), subjects had a SASEQ score of 11, on average, and approximately 66% 
of subjects had made a previous quit attempt in the past 5 years. On average, subjects regarded 
the importance of their current quit attempt as “Very important” and reported being “Very 
determined” for their current quit attempt.80 Average RFQ intrinsic and extrinsic scores were 
5 and 2, respectively. 
 
Mann-Whitney and Chi-squared (𝜒2) tests for differences between observable baseline 
characteristics of treatment and control subjects indicate that the experimental groups are 
balanced across all observable attributes, except for Smoking durationi, Quit attempt in past 5 
yearsi, and RFQ intrinsic scorei. Mann-Whitney tests indicate that control subjects have a 
longer smoking duration (p = 0.077) and higher RFQ intrinsic score (p = 0.097) compared to 
treatment subjects, on average. A 𝜒2 test indicates that a significantly larger proportion of 
control subjects had made a previous quit attempt in the past five years, compared to the 
treatment group (p = 0.090). Clearly it will be important to control for these differences in the 
statistical models to follow.  
 
5.2 Smoking abstinence  
 
This section reports the results of analyses investigating the first research question: Does a low-
cost, low-intensity CM smoking cessation programme increase abstinence? 
 
5.2.1 Initial investigation  
 
Table II reports abstinence proportions for the intervention period (i.e., the four programme 
sessions) and the 3-month follow-up session, for treatment and control subjects.81 During the 
                                                
80 Table I reports the average scores for the Importance of current quiti and Determination of current quiti ordinal 
variables which correspond to “Very important” and “Very determined” for each variable, respectively.  
81 Abstinence proportions are not reported for the baseline session because no subjects were abstinent; their quit 
date was one week after their baseline session.   
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intervention period, the proportion of abstinent subjects in the control group ranges from 
approximately 6% to 10%. Compared to the control group, abstinence proportions during the 
intervention period are higher in the treatment group, ranging from approximately 28% to 45%. 
𝜒2 tests indicate that in each programme session the proportion of abstinent subjects in the 
treatment group is statistically significantly larger compared to the control group (p < 0.05 in 
all cases). In addition, while the intervention-period abstinence proportions oscillate across 
programme sessions for the control group, they increase in each programme session for the 




  Control Treatment Chi-squared test 
Programme session 1  0.106 0.275 0.043 
  (0.312) (0.452)  
Programme session 2 0.064 0.300 0.004 
  (0.247) (0.464)  
Programme session 3 0.085 0.400 0.001 
  (0.282) (0.496)  
Programme session 4 0.064 0.450 0.000 
  (0.247) (0.504)  
3-month follow-up 0.021 0.075 0.233 
  (0.146) (0.267)   
Standard errors in parentheses    
 
At the 3-month follow-up session, approximately 8% and 2% of treatment and control subjects 
are abstinent, respectively, and this difference is not statistically significant. For treatment 
subjects, this corresponds to a 38 percentage point decrease in the proportion of abstinent 
subjects from the end of the intervention period, compared to a 4 percentage point decrease for 
control subjects. This seems to suggest that receiving abstinence-contingent incentives during 
the intervention period may help treatment subjects remain abstinent but that once the 
incentives are removed subjects struggle to remain abstinent. This point requires further 
investigation.  
 
Table III reports transition tables of abstinence for treatment and control subjects. Transition 
tables report the probabilities of transitioning from one category of a categorical variable to 
another category of the same variable, over time. Table IIIa reports results for the intervention 
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period while Table IIIb reports results for the intervention period and the 3-month follow-up 
together.  
 
The results in Table IIIa indicate that in each programme session approximately 2% of control 
subjects who were not abstinent became abstinent in the next session, and approximately 58% 
of control subjects who were abstinent remained abstinent in the next session. In contrast, in 
each programme session approximately 15% of treatment subjects who were not abstinent 
became abstinent in the next session, and approximately 87% of treatment subjects who were 
abstinent remained abstinent in the next session. Both transition probabilities are higher for 
treatment subjects, suggesting that during the intervention period treatment subjects were more 
likely to become abstinent if they were not abstinent in a previous session and were more likely 
to remain abstinent if they were abstinent in a previous session.  
 
TABLE III 
ABSTINENCE TRANSITION TABLES 
TABLE IIIa: INTERVENTION   TABLE IIIb: INTERVENTION & FOLLOW-UP 
Control group  Control group 
  Abstinent       Abstinent    
Abstinent  No  Yes Total   Abstinent  No  Yes Total  
No 0.977 0.023 1  No 0.983 0.017 1 
Yes 0.417 0.583 1  Yes 0.467 0.533 1 
Total  0.929 0.071 1  Total  0.942 0.059 1 
Treatment group  Treatment group 
  Abstinent       Abstinent    
Abstinent  No  Yes Total   Abstinent  No  Yes Total  
No 0.852 0.148 1  No 0.884 0.117 1 
Yes 0.128 0.872 1  Yes 0.351 0.649 1 
Total  0.617 0.383 1  Total  0.694 0.306 1 
 
The results in Table IIIb indicate that when the 3-month follow-up data is included in the 
analysis, the probability of a non-abstinent subject becoming abstinent decreases for treatment 
subjects (15% to 12%) and decreases marginally for control subjects (2.3% to 1.7%). Further, 
the probability of an abstinent subject remaining abstinent decreases for both treatment subjects 
(87% to 65%) and control subjects (58% to 53%).  
 
	 -39- 
In sum, the proportion of abstinent subjects is statistically significantly higher during the 
intervention period for treatment compared to control subjects. In the follow-up session, the 
proportion of abstinent subjects decreases for both treatment and control groups and the 
difference in abstinence rates between the two groups is no longer statistically significant. 
Further, during the intervention period, the probability of a non-abstinent subject becoming 
abstinent and the probability of an abstinent subject remaining abstinent is higher for treatment 
compared to control subjects. Both probabilities decrease for treatment and control groups 
when the 3-month follow-up data is included in the analysis. The next section discusses a more 
detailed parametric analysis of abstinence.  
 
5.2.2 Regression analysis 
 
Table IV presents results of the random-effects probit model investigating whether the low-
cost, low-intensity CM intervention increases abstinence (i.e., whether the probability of being 
abstinent is statistically significantly higher for treatment compared to control subjects).  
 
Regression IVa indicates that the CM programme has an economically and statistically 
significant treatment effect: the likelihood of a treatment subject being abstinent is 13 
percentage points higher compared to control subjects (p = 0.030). Regressions IVb – IVd 
include additional covariates to control for any potential differences between subjects. 
Regression IVb includes demographic characteristics as well as session variables (x2 variables). 
After including the additional covariates, the treatment effect remains statistically and 
economically significant, and increases slightly: the likelihood of a treatment subject being 
abstinent is now 15 percentage points higher compared to control subjects (p = 0.023). In 
addition, compared to African subjects, White subjects have a 17 percentage point higher 
probability of being abstinent (p = 0.063). A Wald test indicates that compared to White 
subjects, Indian subjects have a significantly lower probability of being abstinent (p = 0.075). 
Finally, compared to the baseline session, subjects have a 10 percentage point higher 







ABSTINENCE: RANDOM-EFFECTS PROBIT MODEL 
 Regression IVa Regression IVb Regression IVc Regression IVd 
Treatment 0.127** 0.154** 0.156*** 0.201*** 
 (0.058) (0.068) (0.059) (0.059) 
Age  0.006 0.017 0.025 
  (0.007) (0.013) (0.016) 
Male  0.031 0.044 0.02 
  (0.042) (0.047) (0.062) 
Coloured  0.065 0.043 0.083 
  (0.053) (0.051) (0.066) 
Indian  0.006 0.000 0.033 
  (0.038) (0.048) (0.073) 
White  0.173* 0.201** 0.237*** 
  (0.093) (0.097) (0.077) 
Income (ln)  -0.011 -0.004 -0.021 
  (0.038) (0.041) (0.044) 
Intervention period  0.095** 0.106*** 0.131*** 
  (0.043) (0.041) (0.046) 
3-month follow-up  0.003 0.009 0.015 
  (0.005) (0.010) (0.015) 
Smoking duration   -0.017 -0.027 
   (0.015) (0.020) 
Smoking intensity   -0.002 0.001 
   (0.004) (0.005) 
FTCD score   0.017 0.017 
   (0.013) (0.015) 
MTWS-R score   -0.002 -0.003 
   (0.002) (0.002) 
Baseline CO reading   -0.001 -0.003 
   (0.002) (0.002) 
Quit attempt in past 5 years    0.124** 
    (0.051) 
SASEQ score    0.006 
    (0.006) 
Importance of current quit attempt   0.011 
    (0.038) 
Determination for current quit   0.014 
    (0.042) 
RFQ intrinsic score    -0.018 
    (0.020) 
RFQ extrinsic score    0.012 
    (0.031) 
N 522 492 430 430 
log-likelihood -163.219 -113.783 -101.652 -97.625 
* p<0.10, ** p<0.05, *** p<0.01     
Robust standard errors in parentheses    
Marginal effects reported     
 
As may be expected given the descriptive statistics in Section 5.2.1, subjects’ probability of 
being abstinent at the 3-month follow-up session is not significantly different to baseline. A 
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Wald test indicates that compared to the baseline session, the probability of being abstinent is 
significantly lower in the 3-month follow-up session compared to the intervention period (p = 
0.020). This decline in the cessation rate at the follow-up session is characteristic of CM 
smoking cessation interventions: the programmes increase cessation rates during the 
intervention period while abstinence-contingent incentives are in place, but cessation rates 
typically decline once the incentives are removed.  
 
Regression IVc includes variables related to cigarette smoking (x3 variables). The treatment 
effect remains statistically and economically significant (p = 0.008) and no variables related to 
cigarette smoking have a statistically significant effect on the probability of abstinence. 
Regression IVd includes variables related to quitting smoking (x4 variables). The treatment 
effect remains statistically and economically significant, and increases slightly: the likelihood 
of a treatment subject being abstinent is 20 percentage points higher compared to control 
subjects (p = 0.001). In addition, subjects who had made a quit attempt in the past 5 years have 
a 12 percentage point higher probability of being abstinent compared to those subjects who had 
not made a previous quit attempt (p = 0.024).82  
 
As a robustness check, Model B:I in Table B (see Appendix) reports the results of a pooled 
Probit model.83 Except for Agei which becomes statistically significant (i.e., subjects who are 
one year older have a 3 percentage point higher probability of being abstinent; p = 0.040), the 
results of the pooled Probit model are qualitatively identical to those of the random-effects 
probit model. The random-effects probit model is the preferred model given that the estimate 
of 𝜌 = 0.778, which represents the proportion of the total variance contributed by the panel-
level variance component, is statistically significantly different to zero, indicating that one must 
incorporate the serial dependence of the error terms and model them statistically (p < 0.001).  
 
In sum, the results in Section 5.2 suggest that a low-cost, low-intensity CM programme 
increases smoking cessation rates in a sample of treatment-seeking students at UCT. There is 
a statistically significant treatment effect, that is robust across different models and multiple 
                                                
82 Quit attempt in the past 5 yearsi is a variable that is not balanced across treatment and control groups at baseline. 
Both Smoking durationi and RFQ intrinsic scorei, which are significantly different for treatment and control 
subjects at baseline, do not have a statistically significant effect on the likelihood of abstinence. 
83 The Sessioni variables could not be included in the pooled Probit model because it does not account for the 
panel structure of the data. The base category, baseline session, is a perfect predictor of the response probability 
because no subjects are abstinent in the baseline session, which means the variable drops out of the analysis. 
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specifications, which increases the likelihood of abstinence by approximately 13-20%. 
However, noticeable declines in cessation rates are evident at the 3-month follow-up across 
treatment and control groups.  
 
5.3 Smoking intensity  
 
This section reports the results of analyses investigating the second research question: Does a 
low-cost, low-intensity CM programme reduce smoking intensity amongst those subjects who 
failed to remain abstinent? 
 
5.3.1 Initial investigation 
 
Table V reports average smoking intensity across the baseline session, the intervention period, 







Baseline 9.889 9.821 0.756 
  (5.180) (6.696)  
Programme session 1  3.056 4.296 0.139 
  (2.496) (3.289)  
Programme session 2 2.878 3.518 0.584 
  (2.280) (3.155)  
Programme session 3 3.155 4.020 0.405 
  (2.597) (3.625)  
Programme session 4 4.012 5.565 0.102 
  (3.775) (4.187)  
3-month follow-up 6.305 5.795 0.909 
  (4.826) (3.379)   
Standard errors in parentheses    
 
At baseline, both treatment and control subjects were smoking approximately 10 cigarettes per 
day on average.84 Smoking intensity decreases sharply from baseline to the intervention period. 
During the intervention period, the smoking intensity of non-abstinent control subjects 
                                                
84 These are the same statistics reported in Table I because no subjects were abstinent at baseline. 
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oscillates, ranging from 3 to 4 cigarettes per day on average, whereas the smoking intensity of 
non-abstinent treatment subjects ranges from 4 to 6 cigarettes per day. The smoking intensity 
of non-abstinent treatment subjects is higher compared to non-abstinent control subjects in 
each programme session during the intervention period, however, Mann-Whitney tests indicate 
that none of the differences are statistically significant. Finally, smoking intensity at the 3-
month follow-up is 6 cigarettes per day for both non-abstinent treatment subjects and non-
abstinent control subjects and this difference is not statistically significant.  
 
In sum, initial descriptive statistics of smoking intensity of those subjects who failed to remain 
abstinent indicate that smoking intensity is lower during the intervention period and at follow-
up, as compared to baseline levels. Further, there is no statistically significant difference in the 
smoking intensity of non-abstinent treatment subjects and non-abstinent control subjects in any 
of the sessions. The next section conducts a more detailed parametric analysis of smoking 
intensity. 
 
5.3.2 Regression analysis 
 
Table VI presents results of the random-effects negative binomial model investigating whether 
a low-cost, low-intensity CM intervention decreases the smoking intensity of those subjects 
who failed to remain abstinent (i.e., whether smoking intensity is statistically significantly 
lower for treatment compared to control subjects).  
 
In contrast to expectations, Regression VIa indicates that the smoking intensity of non-
abstinent treatment subjects is statistically significantly higher compared to non-abstinent 
control subjects (p = 0.089). Regressions VIb - VId include additional covariates to control for 
any potential differences between subjects. Regression VIb includes demographic 
characteristics as well as session variables (x2 variables). In contrast to Regression VIa, the 
results indicate that non-abstinent treatment subjects do not have a statistically significantly 
higher smoking intensity than non-abstinent control subjects (p = 0.505). In addition, compared 
to African subjects, Coloured subjects have a higher smoking intensity (p = 0.040). Finally, 
compared to the baseline session, non-abstinent subjects have a statistically significantly lower 
smoking intensity during the intervention period and at the 3-month follow-up (p < 0.001 in 
both cases). A Wald test indicates that the reduction in the smoking intensity from baseline is 
larger in the intervention period compared to the 3-month follow-up session (p < 0.001). Thus, 
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the Regression VIb results suggest that while there is no treatment effect, the programme as a 
whole reduces the smoking intensity of non-abstinent subjects and that, while still statistically 
significant, this reduction in smoking intensity is smaller at the 3-month follow-up than during 
the intervention period. This finding is in line with the preliminary investigation of smoking 
intensity in Section 5.3.1. 
 
Regression VIc includes variables related to cigarette smoking (x3 variables). The results 
indicate that the “programme effect” is still present: compared to baseline, smoking intensity 
is statistically significantly lower during the intervention period and at the 3-month follow-up 
(p < 0.001 in both cases), where the reduction in smoking intensity from baseline is statistically 
significantly smaller at the 3-month follow-up session compared to the intervention period (p 
< 0.001). In addition, older subjects have a statistically significantly higher smoking intensity, 
on average (p = 0.041). Subjects who have been smoking for longer and subjects with a higher 
baseline FTCD score have a statistically significantly higher smoking intensity on average (p 
= 0.003 and p < 0.001, respectively). Regression VId includes variables related to quitting 
smoking (x4 variables). The results are in line with those of Regression VIc. In addition, 
subjects who reported being more determined to quit smoking at baseline have a statistically 
significantly lower smoking intensity on average (p = 0.075). 
 
As robustness checks Table B (see Appendix) reports the results of a random-effects poisson 
model and a pooled negative binomial model. In Model B:II, except for Malei which becomes 
statistically significant (i.e., male subjects have a higher smoking intensity on average; p = 
0.077), the results of the random-effects poisson model are qualitatively identical to those of 
the random-effects negative binomial model. In Model B:III, Malei is also positive and 
statistically significant (p = 0.014). In addition, Coloured subjects have a statistically 
significantly higher smoking intensity compared to African subjects (p = 0.092). The remaining 
















Treatment 0.998* 0.412 0.39 0.189 
 (0.587) (0.618) (0.516) (0.492) 
Age  0.105 -0.304** -0.267* 
  (0.111) (0.149) (0.147) 
Male  0.165 0.947 0.839 
  (0.713) (0.579) (0.585) 
Coloured  1.561** 1.102 1.069 
  (0.760) (0.682) (0.669) 
Indian  0.899 0.006 -0.176 
  (0.841) (0.721) (0.693) 
White  1.243 0.678 0.524 
  (0.873) (0.748) (0.713) 
Income (ln)  0.235 0.434 0.339 
  (0.494) (0.418) (0.402) 
Intervention period  -6.368*** -6.337*** -6.281*** 
  (0.546) (0.501) (0.489) 
3-month follow-up  -3.906*** -3.969*** -3.904*** 
  (0.586) (0.573) (0.568) 
Smoking duration   0.463*** 0.494*** 
   (0.157) (0.162) 
FTCD score   0.576*** 0.696*** 
   (0.146) (0.149) 
MTWS-R score   0.022 0.023 
   (0.021) (0.021) 
Baseline CO reading   0.04 0.039 
   (0.030) (0.030) 
Quit attempt in past 5 years    -0.381 
    (0.573) 
SASEQ score    0.014 
    (0.054) 
Importance of current quit 
attempt    -0.269 
    (0.389) 
Determination for current quit    -0.784* 
    (0.440) 
RFQ intrinsic score    0.094 
    (0.175) 
RFQ extrinsic score    -0.023 
    (0.266) 
N 387 372 361 361 
log-likelihood -1022.2783 -887.16425 -851.04129 -847.03206 
* p<0.10, ** p<0.05, *** p<0.01     
Standard errors in parentheses     
Marginal effects reported     
 
In sum, the results in Section 5.3 suggest that the low-cost, low-intensity CM smoking 
cessation programme does not reduce the smoking intensity of those subjects who failed to 
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remain abstinent (i.e., there is no smoking intensity treatment effect). However, the programme 
as a whole tends to reduce the smoking intensity of all non-abstinent subjects (i.e., both non-
abstinent treatment and non-abstinent control subjects), but this effect, while still significant, 
appears to decline at the 3-month follow-up.  
 
5.4 Potential biases and robustness checks 
 
The review of the CM literature outlined a number of potential sources of bias that may limit 
one’s ability to draw valid and robust causal inferences (i.e., selection bias, performance bias, 
attrition bias, and “deception” bias). This section discusses two potential biases that threaten 
the internal validity of the RCT – namely, performance bias and attrition bias - and analyses 
the robustness of the smoking abstinence and smoking intensity results in light of these issues. 
This section builds on the discussions in Section 5.2.2 and Section 5.3.2 which demonstrate 
the robustness of the smoking abstinence and smoking intensity results to different regression 
models.  
 
5.4.1 Performance bias 
 
Performance bias refers to systematic differences between groups’ outcomes that arise from 
knowledge of treatment allocation, rather than the treatment itself. While blinding of 
participants may reduce the risk of performance bias, the explicit mechanism of rewards in CM 
interventions makes complete blinding almost impossible. As mentioned, we chose to reveal 
treatment information to treatment subjects (treatment subjects were told that they had been 
randomly selected to receive abstinence-contingent rewards in the programme sessions) but 
not to control subjects. This reduces the possibility of a John Henry, or resentment and 
demoralisation effect, but, the possibility for a Hawthorn effect remains.  
 
While the above design choice was made to try reduce the risk of performance bias, we 
randomised at the level of the individual so we could not mitigate the problem entirely. In 
particular, we recruited individuals within a single university and randomised them into the 
treatment or control group, which means that subjects may coincidently know other 
participants in the study or subjects may have signed up together. Subjects may have therefore 
learned of the other treatment arms through other study participants and this knowledge, rather 
than treatment itself, may cause systematic differences between the outcomes of the treatment 
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and control groups. 
 
Aware of this potential issue, I included questions in the fourth programme session’s 
questionnaire, which asked subjects whether they knew other students taking part in the study 
and how many other students they knew who were taking part. Approximately 66% of subjects 
knew at least one other subject taking part in the study. A 𝜒2 test indicates that this percentage 
does not differ across treatment and control groups (p = 0.573). In addition, subjects knew 2 
other study participants on average. A Mann-Whitney test indicates that this does not differ 
across treatment and control groups (p = 0. 811).  
 
Table VII reports the results of a random-effects probit model of abstinence (Model VIIa) and 
a random-effects negative binomial model of smoking intensity (Model VIIb) with an 
additional variable to capture any effect that knowing other study participants may have: Know 
others in the studyi is a binary variable equal to one if the subject knows at least one other study 
participant and equal to zero otherwise. The abstinence results in Model VIIa are qualitatively 
identical to those in Table IV and the Know others in the studyi variable is not statistically 
significant, suggesting that the abstinence results reported in Table IV are robust to this 
potential bias. The intensity results in Model VIIb are qualitatively identical to those in Table 
VI, however, Determination for current quiti is no longer statistically significant. In addition, 
Know others in the studyi is statistically significant and positive, suggesting that subjects who 
know other study participants have a higher smoking intensity on average. Thus, knowing other 





ROBUSTNESS: PERFORMANCE BIAS 
 Model VIIa Model VIIb 
 RE Probit RE Negative Binomial 
Treatment 0.194*** 0.134 
 (0.058) (0.500) 
Age 0.024 -0.261* 
 (0.017) (0.149) 
Male 0.035 0.713 
 (0.062) (0.609) 
Coloured 0.082 0.691 
 (0.064) (0.703) 
Indian 0.046 -0.713 
 (0.078) (0.721) 
White 0.248*** 0.121 
 (0.080) (0.766) 
Income (ln) -0.015 0.335 
 (0.045) (0.414) 
Intervention period 0.144*** -6.233*** 
 (0.045) (0.512) 
3-month follow-up 0.016 -3.922*** 
 (0.017) (0.588) 
Smoking duration -0.029 0.535*** 
 (0.021) (0.165) 
Smoking intensity 0.002  
 (0.005)  
FTCD score 0.016 0.710*** 
 (0.017) (0.153) 
MTWS-R score -0.003 0.032 
 (0.002) (0.021) 
Baseline CO reading -0.003 0.027 
 (0.002) (0.030) 
Quit attempt in past 5 years 0.128** -0.509 
 (0.052) (0.591) 
SASEQ score 0.006 0.039 
 (0.007) (0.056) 
Importance of current quit attempt 0.015 -0.248 
 (0.044) (0.401) 
Determination for current quit 0.013 -0.734 
 (0.045) (0.451) 
RFQ intrinsic score -0.015 0.028 
 (0.023) (0.176) 
RFQ extrinsic score 0.010 -0.011 
 (0.033) (0.272) 
Know others in the study -0.046 1.051** 
 (0.056) (0.501) 
N 414 345 
log-likelihood -96.232643 -808.36894 
* p<0.10, ** p<0.05, *** p<0.01   
Notes: RE = Random effects   
Standard errors in parentheses. SEs are robust in Model VIIa 
Marginal effects reported    
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5.4.2 Attrition bias 
 
Attrition occurs when outcomes cannot be measured for some study participants, which creates 
problems of missing data and which, in turn, reduces statistical power (Glennerster and 
Takavarasha 2013). The potential for attrition bias occurs when there is differential attrition - 
in particular, across treatment and control groups - which undermines the validity of the 
experiment. As mentioned, students are a particularly convenient sample because they are easy 
to recruit and easy to track. Nevertheless, additional design choices were made to reduce the 
risk of attrition bias. First, attendance was incentivized: show-up fees were provided in each 
session (R50 at baseline and in each of the programme sessions, and R200 in the follow-up 
sessions) and a R200 attendance bonus was provided in the final programme session if subjects 
had attended all four programme sessions. To ensure the salience of the attendance incentives, 
subjects were consistently reminded of the attendance incentives at the end of each session. 
Second, subjects were sent an email and two SMS reminders to remind them of each of their 
sessions and the attendant show-up fee.  
 
While the above-mentioned design choices were made to reduce the risk of attrition bias, we 
randomised at the level of the individual which meant that subjects may coincidently know 
other participants in the study or subjects may have signed up together. This not only introduces 
the potential for performance bias, but may also lead to attrition bias: subjects in the control 
group who find out about the treatment group via other study participants may be more likely 
to drop out of the study (Glennerster and Takavarasha 2013).   
 
This dissertation defines attrition as those subjects who dropped out of the study after the 
baseline session and did not arrive for another session. Subjects who missed one (or more than 
one) programme session, but arrived for a later session are not considered to have dropped out 
because smoking abstinence and smoking intensity outcomes could still be measured for those 
subjects; a RA completed the TLFB calendar with the subject for the period that they had 
missed.85 In addition, subjects who dropped out after sign-up for the baseline session but before 
                                                
85 Abstinence over the “missed” period was not incentivised for treatment subjects because they could not provide 
a CO reading for the relevant period and therefore could not meet both abstinence conditions: self-reported 
abstinence for the past 7 days and a CO reading of 6 ppm or less. Thus, treatment subjects had no financial 
incentive to misreport their smoking abstinence or intensity for the “missed” period – see Section 6 for a discussion 
of deception.  
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the baseline session itself (i.e., the official start of the CM programme) are not considered to 
have dropped out.86  
 
The overall attrition rate is approximately 15%. Specifically, 13 subjects dropped out of the 
study at different points: one subject dropped out after the baseline session, seven subjects 
dropped out after the first programme session,87 one subject dropped out after the second 
programme session, and four subjects dropped out after the fourth programme session (i.e., 
they did not arrive for the 3-month follow-up session). Of the subjects who dropped out, 9 were 
control subjects and 4 were treatment subjects, which corresponds to 19% and 10% attrition 
rates, respectively. A 𝜒2 test reveals that the attrition rate is not statistically different across the 
treatment arms, indicating that there is no differential attrition. 
 
Table VIII reports non-attendance/absenteeism proportions (i.e., the proportion of subjects that 
were absent) in each session, for treatment and control groups.88 The results indicate that non-
attendance proportions range from 2% to 20%. The difference in non-attendance proportions 
is not statistically significantly different for treatment and control groups, except in the fourth 




  Control Treatment 𝜒2 test 
Programme session 1  0.064 0.025 0.389 
Programme session 2 0.213 0.100 0.154 
Programme session 3 0.192 0.100 0.233 
Programme session 4 0.192 0.025 0.015 
3-month follow-up 0.192 0.100 0.233 
 
When there are missing data in a RCT, a common sensitivity analysis is to explore “best” and 
“worst” case scenarios by replacing missing values with “good” outcomes in the one group and 
with “bad” outcomes in the other group (Glennerster and Takavarasha 2013; Sterne et al. 
                                                
86 As mentioned, 105 subjects signed up for the baseline session and were randomised into the treatment or control 
group, and 87 subjects arrived for the baseline session (i.e., 18 subjects, 12 treatment subjects and 6 control 
subjects, dropped out before the start of the programme; see Figure 2). Importantly, those subjects who dropped 
out before the baseline session had no information about treatment allocation. Drop out is, therefore, unrelated to 
treatment allocation and should not be considered a threat to the validity of the experiment. 
87 One subject formally withdrew from the study after the first programme session for health reasons unrelated to 
the CM programme.  
88 The 3-month follow-up non-attendance proportions are equivalent to the attrition rates. 
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2009).89 In terms of the abstinence outcomes, a “best” case scenario would be if all absent 
treatment subjects were abstinent and all absent control subjects were not abstinent, and a 
“worst” case scenario would be if all absent treatment subjects were not abstinent and all absent 
control subjects were abstinent. As mentioned in Section 4, the abstinence analysis thus far has 
adopted the standard assumption that non-attenders, both treatment and control, are not 
abstinent.  A “best” case analysis contributes little to the analysis: adopting the unlikely 
assumption that all absent treatment subjects are abstinent and all absent control subjects are 
not abstinent, the results simply confirm those found when the standard assumption is adopted. 
A “worst” case analysis is useful because it bounds the estimated results from below.   
 
Table IX reports the results of a random-effects probit of abstinence in the “worst” case 
scenario. The results indicate that there is no statistically significant treatment effect. This 
suggests that the treatment effect may not be robust to differential reporting of abstinence. But 
what weight should we give to this lower-bound estimate? The TLFB data on those subjects 
who were absent for a session(s) but arrived for a later one, shows that only one person reported 
being abstinent on a week that they did not attend. This implies that adopting the standard 




                                                
89 Such a sensitivity analysis is possible with the binary Abstinenceit outcome variable because there is an obvious 
good and bad outcome (Sterne et al. 2009). In contrast, such a sensitivity analysis is not possible with the 
continuous Smoking intensityit outcome variable because there is no obvious good or bad outcome.  
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TABLE IX 
ROBUSTNESS: Attrition bias 
 Model 1 













Income (ln) 0.004 
 (0.054) 
Intervention period 0.162*** 
 (0.047) 
3-month follow-up 0.046 
 (0.029) 
Smoking duration -0.025 
 (0.022) 
Smoking intensity 0.001 
 (0.007) 
FTCD score 0.003 
 (0.022) 
Baseline CO reading -0.004 
 (0.003) 
Quit attempt in last 5 years 0.093 
 (0.068) 
SASEQ score 0.005 
 (0.007) 
Importance of current quit attempt 0.052 
 (0.045) 
Determination for current quit -0.034 
 (0.054) 
RFQ intrinsic score -0.029 
 (0.024) 




* p<0.10, ** p<0.05, *** p<0.01 
Robust standard errors in parentheses 





5.5 What did subjects think about their quit attempt? 
 
Sections 5.2 and 5.3 report the results of a quantitative analysis of smoking abstinence and 
smoking intensity. This section aims to build on the quantitative analysis by looking at the 
qualitative data that were collected. The questionnaire in the final programme session asked 
subjects to list the reasons why they thought they had remained, or failed to remain, abstinent, 
and what approach/aid they had adopted to help them with their quit attempt. In addition, 
treatment subjects were asked whether they thought that the R150 abstinence-contingent 
incentive helped with their quit attempt and were asked to provide reasons for their answer. 
Albeit subjective, subjects’ answers may provide insights into why some subjects remained 
abstinent, while others did not.  
 
Regarding the reasons for a failed quit attempt, approximately 54% of subjects reported stress 
(academic and/or personal) and approximately 28% of subjects reported environmental 
factors/triggers (e.g., parties, alcohol, and friends or housemates who smoke) as reasons for 
smoking. Some less commonly identified reasons include a poor mindset, a concern for weight 
gain, boredom, a lack of psychological support, an inability to find a sufficient substitute, and 
a high baseline smoking intensity which was possible to reduce but not completely curb. 
Regarding the reasons for a successful quit attempt, subjects’ responses varied considerably. 
The responses include: a good mindset, the use of substitutes (e.g., e-cigarettes, chewing gum, 
sweets), a desire to prove to that they could quit, health and financial reasons, social pressure 
and support, and reputation.90 
 
Regarding the approach/aid used to help with the quit attempt, three main approaches were 
used: approximately 45% of subjects went “cold-turkey,” approximately 27% of subjects used 
substitutes (e.g., e-cigarettes, NRT, marijuana, chocolates, hookah pipes, carrots, water), and 
approximately 22% of subjects reduced their smoking intensity as a step towards complete 
abstinence. Subjects cite several different techniques for reducing their smoking intensity, 
which include setting a daily limit and reducing it over time, sharing cigarettes with friends, 
rolling their own cigarettes rather than buying boxes, and buying single cigarettes rather than 
boxes. Several subjects also cite exercise and meditation as aids adopted to help with their quit 
attempt.  
                                                
90 One subject was studying medicine and noted that smoking damaged his reputation.  
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Regarding treatment subjects’ responses to whether they thought that the R150 abstinence-
contingent reward helped with their quit attempt, 65% of treatment subjects thought that the 
incentive helped.91 Subjects cite several reasons for why the incentive helped, which include 
that it was a good size, it served as an additional source of motivation, it helped to keep them 
focused on their goal, and it helped with the initial phase of the quit attempt. Several subjects 
note that while the incentive helped keep them on track when they had “smaller” cravings, it 
could not help with more intense cravings. Of the subjects who thought the incentive had not 
helped, approximately 83% felt that the incentive was not large enough to outweigh the 
“power” of their cravings and their addiction. Other subjects cited that they were intrinsically 
motivated to quit smoking and felt that they did not need to be extrinsically motivated by means 
of a financial incentive.  
  
The preceding qualitative analysis highlights that approximately 82% of subjects struggled to 
remain abstinent because of academic or personal stress, and environmental factors. Further, 
just under half of the subjects went “cold-turkey,” while other subjects either used substitutes 
to help with their quit attempt or aimed to achieve abstinence by reducing their smoking 
intensity over time. Finally, while a relatively large number of subjects reported that they 
thought the abstinence-contingent incentives helped with their quit attempt, those subjects who 
thought it did not help cited that the incentive was not large enough to outweigh their cravings.  
 
6. DISCUSSION AND CONCLUSION 
 
This research investigated whether a low-cost, low-intensity CM smoking cessation 
programme could be an effective form of treatment for tobacco addiction in treatment-seeking 
university students. Specifically, this dissertation focused on two questions: Does a low-cost, 
low-intensity CM smoking cessation programme bring about abstinence from smoking and, if 
not, does it reduce the smoking intensity of non-abstainers? 
 
With regard to the first question, the results in Section 5.2 indicate that there is a statistically 
significant treatment effect, that is robust across different models and multiple specifications, 
                                                
91 While 65% of treatment subjects thought that the incentive had helped with their quit attempt, clearly not all of 
those subjects managed to remain abstinent for the entire programme. 
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which increases the likelihood of abstinence by approximately 13-20%. However, there are 
noticeable declines in cessation rates at the 3-month follow-up across treatment and control 
groups. These findings suggest that a low-cost, low-intensity CM programme increases 
smoking cessation rates in treatment-seeking student smokers, but, cessation rates are not 
maintained beyond the intervention period. Importantly, these results replicate the findings in 
the literature: CM interventions are effective at increasing cessation rates but cessation rates 
tend to decline after the intervention period once the abstinence-contingent incentives are 
removed. It is interesting that we managed to replicate the standard result with a low-cost, low-
intensity smoking cessation programme in a university setting, which points to the potential 
value and feasibility of conducting this type of intervention with this sample. But future 
research will want to investigate how the programme could be adjusted to help subjects achieve 
continuous abstinence, beyond the end of the intervention period.  
 
The qualitative analysis in Section 5.5 suggests changes to the cessation programme that may 
prove to be effective in this regard. First, 82% of subjects reported struggling to remain 
abstinent because of academic or personal stress, and environmental factors. The CM 
programme was conducted during UCT’s third term and did not continue into the fourth and 
final term which is considered the most stressful time of year for students due to an 
accumulating work load and end-of-year exams. Subjects’ responses suggest that increasing 
the duration of the programme, so that it starts before their work load begins to accumulate and 
ends after the end-of-year exams, might help them to achieve continuous abstinence. In 
addition, an escalating incentive schedule (as opposed to the uniform schedule used in this 
study), in combination with the increased programme duration, may help maintain cessation 
rates: students would receive smaller incentives during the less stressful time of year and would 
receive larger incentives during the most stressful time of year. In principle, increasing the 
duration of the programme and implementing an escalating incentive schedule need not 
increase the cost or complexity of the CM programme: the “same” total available abstinence-
contingent rewards could be allocated over a longer period with a different schedule of 
payments.  
 
Second, of the subjects who thought the abstinence-contingent incentives had not helped with 
their quit attempt, approximately 83% felt that the incentive was not large enough to outweigh 
the “power” of their cravings and their addiction. This suggests that the incentive magnitude 
was not sufficiently large to compete with the reinforcing attributes of tobacco use and that 
	 -56- 
increasing the magnitude of the incentives might help those subjects overcome their cravings 
and establish continuous abstinence. The increase in the incentive magnitude need not be large 
because university students’ incomes are still low relative to the general population. Future 
research could investigate what incentive magnitude would be sufficiently large to compete 
with the tobacco cravings of these “hard-to-treat” subjects. In addition, one could test whether 
cessation rates increase relative to those found in this programme and whether they are 
maintained.  
 
With regard to the second research question (i.e., whether the CM programme decreased the 
smoking intensity of non-abstainers), the results in Section 5.3 indicate that the programme 
does not have a statistically significant effect on the smoking intensity of non-abstainers. 
However, the programme as a whole tends to reduce the smoking intensity of all non-abstinent 
subjects (i.e., both non-abstinent treatment and non-abstinent control subjects), although this 
effect, while still significant, appears to decline at the 3-month follow-up. This result should, 
however, be read with caution. Specifically, the effect may in part be driven by UCT’s new 
smoking policy which was implemented shortly before the start of the smoking cessation 
programme and restricts where individuals can smoke on campus. When asked about the 
university’s new smoking policy, almost all subjects (approximately 95%) knew about the 
policy change and 44% of subjects thought that it might help them with their quit attempt. 𝜒2 
tests indicate that neither of these responses were significantly different across treatment and 
control groups (p = 0.391 and p = 0.992, respectively). While the policy change may have 
played a role in the decreased smoking intensity, the fact that the decrease was smaller in the 
follow-up session, compared to the intervention period, suggests that the weekly monitoring 
during the intervention period did play a role in decreasing intensity.  
 
Section 5.4 addressed two potential sources of bias that may limit one’s ability to draw valid 
and robust causal inferences – namely, performance bias and attrition bias - and analysed the 
robustness of the smoking abstinence and smoking intensity results in light of those issues. 
With regard to performance bias, randomisation at the level of the individual meant that a large 
number of subjects (approximately 66%) knew at least one other subject taking part in the 
study. Thus, subjects may have learnt of the other treatment arms through other study 
participants and this knowledge, rather than treatment itself, may cause systematic differences 
between the outcomes of the treatment and control groups.  
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As a robustness check, the regression models for smoking abstinence and intensity were re-
run, including an additional binary variable indicating whether the subject knew at least one 
other study participant. The results indicate that knowing another participant has no observable 
effect on the abstinence results, but knowing another participant does appear to increase the 
smoking intensity of non-abstainers.  
 
It would be interesting to conduct a social network analysis of the participants in the study 
because this may allow one to tease out the effect of knowing other study participants: 
Specifically, does knowing an abstinent participant increase one’s likelihood of being 
abstinent? In addition, is there a relationship between knowing other people in the study and 
the smoking intensity of non-abstinent subjects? We asked subject for the names of the other 
participants that they knew, so such an analysis will be possible. Alternatively, future research 
may consider trying to harness social influences by explicitly “designing this into” the 
programme. For example, Halpern et al. (2015), who found a significant treatment effect that 
lasted into the follow-up, grouped subjects so that they not only received individual abstinence-
contingent incentives, but also received additional rewards for each successful quitter in their 
group.  
 
With regard to attrition bias, the study had an overall attrition rate of 15% and this rate did not 
differ significantly across treatment and control groups. As a robustness check, a worst-case 
random-effects probit was run, where all absent treatment subjects were assumed to be not 
abstinent and all absent control subjects were assumed to be abstinent. The results indicate that 
the abstinent treatment effect is no longer statistically significant, but this worst-case 
assumption is obviously a very strong one, particularly because the TLFB data on those 
subjects who did not attend their session shows that only one subject reported being abstinent.   
 
An additional source of bias, not discussed in Section 5.4, is deception bias, which refers to the 
possibility of systematic differences in reports of abstinence amongst treatment and control 
subjects; treatment subjects may be tempted to misreport abstinence because of the contingent 
nature of the rewards. Biochemically verifying abstinence is important for mitigating such 
deception. For a subject to be classified as abstinent they had to meet two conditions: they had 
to report, in the TLFB section of the questionnaire, being abstinent in the previous 7 days and 
they had to have a CO reading of 6 ppm or less. Assessing the disparities between self-reports 
of abstinence and CO readings provides an estimate of the “rate of deception.” Looking at the 
	 -58- 
data reveals that there were 8 instances where subjects self-reported being abstinent but had a 
CO reading greater than 6 ppm. This corresponds to a relatively low deception rate of 2.3%. 
These misreports occurred across 7 subjects (one had a mismatch twice), and all but one were 
treatment subjects. So, it is clear that there is a differential deception rate across the treatment 
and control groups, and this highlights the importance of biochemical verification.  
 
Two further points warrant discussion. First, the qualitative analysis in Section 5.5 revealed 
that 27% of subjects used some form of substitute to help with their quit attempt. While the 
aim of the programme was to target cigarette smoking, it is useful to get a sense of whether, 
and how much, nicotine substitutes were consumed. TLFB data was collected on e-cigarette 
and NRT use. During the intervention period, three subjects (i.e., 3.5% of our sample) used 
nicotine replacement therapy; two were treatment subjects and one was a control subject. In 
addition, 31 subjects (approximately 36% of the sample) used e-cigarettes: 14 subjects in the 
control group and 17 subjects in the treatment group. Conditional on use, control subjects used 
e-cigarettes 3 days per week, on average, and treatment subjects used e-cigarettes 5 days per 
week, on average; this difference is not significantly different (p = 0.1196). So, while 
approximately one-quarter of the sample used substitutes, this did not differ across treatment 
and control groups and cannot, therefore, account for the abstinent treatment effect.  
 
Second, study funding limited the number of subjects that could be recruited, and subject drop 
out between randomization and the baseline session led to a relatively small sample (n = 87). 
The sample size is comparable with and, actually larger than, a number of studies in the 
literature (Alessi and Petry 2014; Crowley et al. 1995; Ledgerwood and Petry 2010; Paxton 
1980, 1981; Rand et al. 1989). Notwithstanding this issue, the study serves as a useful pilot for 
future research, but a larger sample would lend more credence to the results.  
 
In sum, the study found that a low-cost, low-intensity CM smoking cessation programme, 
conducted on a sample of treatment-seeking university students, increased the likelihood of 
abstinence. While the abstinent treatment effect declines after the end of the intervention 
period, there are ways in which the programme could be adjusted to try to maintain cessation 
rates. To the extent that this proves successful, universities may want to consider offering CM 
programmes as part of the health care services that they provide to students because increasing 
student smoking cessation rates will reduce tobacco-related morbidity and thereby decrease the 
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Note: both previous abstinence & attendance = NA 
ABSTINENCE   
• For today’s session you receive the R150 payment because 
you were abstinent in the past week  
• Well done for remaining abstinent! 
• Because the R150 payment is for abstinence, you only 
receive it because you were abstinent in the past week 
• It’s great that you were abstinent in the past week, and the 
goal is to remain abstinent going forward. If, when you come 
in next week, we find that you are abstinent for the week 
prior, you will receive R150 payment for abstinence again 
• Remember that if you are struggling with your quit attempt, 
you can refer to the quit guide we provided you with (it is 
also on the Vula site) 
ATTENDANCE 
• You also receive the R50 show-up fee just for attending 
today’s session 
• It’s great, and we really appreciate, that you attended today’s 
session 
• Because the show-up fee is for simply attending the session, 
you would obviously have received this, even if you weren’t 
abstinent in the past week 
• It’s important that you keep attending all your sessions, 
irrespective of whether you are abstinent in the previous 
week, because we don’t only care about whether you were 
abstinent, we also want to know, if you weren’t abstinent, 
when and how much you have been smoking in the previous 
week  
• That’s why, like with today’s session, you will receive the 
R50 show-up fee at each session, irrespective of whether you 
remained abstinent in the previous week  
• Also remember that if you keep attending all sessions this 
term, you will receive a R200 bonus in the last session this 
term, irrespective of whether you remained abstinent 
throughout the term 
• Here is your payment for today. That R200 in total; the R150 
(for abstinence in the past week) and the R50 show-up fee. 
Please can you check the amount and sign the payment 
receipt. 
• Thanks for coming to today’s session. We will see you at the 
same time next week. SUBJECT LEAVES. 
ABSTINENCE   
• For today’s session you receive the R150 payment because you 
were abstinent in the past week  
• Well done for remaining abstinent! 
• Because the R150 payment is for abstinence, you only receive 
it because you were abstinent in the past week 
• It’s great that you were abstinent in the past week AND the 
week before that. The goal is to remain abstinent going 
forward. If, when you come in next week, we find that you are 
abstinent for the week prior, you will receive R150 payment for 
abstinence again 
• Remember that if you are struggling with your quit attempt, you 
can refer to the quit guide we provided you with (it is also on 
the Vula site) 
ATTENDANCE 
• You also receive the R50 show-up fee for attending today’s 
session 
• It’s great, and we really appreciate, that you attended today’s 
session 
• Because the show-up fee is for simply attending the session, 
you would obviously have received this, even if you weren’t 
abstinent in the past week 
• It’s important that you keep attending all your sessions, 
irrespective of whether you are abstinent in the previous week, 
because we don’t only care about whether you were abstinent, 
we also want to know, if you weren’t abstinent, when and how 
much you have been smoking in the previous week 
• That’s why, like with today’s session, you will receive the R50 
show-up fee at each session, irrespective of whether you 
remained abstinent in the previous week  
• Also remember that if you keep attending all sessions this term, 
you will receive R200 in the last session (in the last week of 
term), irrespective of whether you remained abstinent 
throughout the term 
• Thanks for coming to today’s session. We will see you at the 
same time next week. SUBJECT LEAVES. 
ABSTINENCE   
• For today’s session you receive the R150 payment 
because you were abstinent in the past week  
• Well done for remaining abstinent! 
• Because the R150 payment is for abstinence, you only 
receive it because you were abstinent in the past week 
• It’s great that you were abstinent in the past week AND 
the weeks before that. The goal is to remain abstinent 
going forward.  
• Remember that if you are struggling to remain abstinent, 
you can refer to the quit guide we provided you with (it 
is also on the Vula site) 
ATTENDANCE 
• You receive the R50 show-up fee for attending today’s 
session 
• It’s great, and we really appreciate, that you attended 
today’s session 
• Because the show-up fee is for simply attending the 
session, you would obviously have received this, even if 
you weren’t abstinent in the past week  
• [If DID attend all four sessions] You attended all the 
sessions this term so you receive the R200 bonus 
payment  
• [If DIDN’T attend all four sessions] You unfortunately 
don’t receive the R200 bonus payment because you 
didn’t attend all your sessions this term 
• There are still two more follow-up sessions, but we will 
email you to sign up for them closer to the time. 
Remember that you will receive R200 for attending each 






 ABSTINENCE   
• For today’s session you receive the R150 payment because you 
were abstinent in the past week  
• Well done for remaining abstinent! 
• Because the R150 payment is for abstinence, you only receive 
it because you were abstinent in the past week 
• It’s great that you were abstinent in the past week EVEN 
THOUGH you weren’t abstinent in the week before that. The 
goal is to remain abstinent going forward. If, when you come 
in next week, we find that you are abstinent for the week prior, 
you will receive R150 payment for abstinence again 
• Remember that if you are struggling with your quit attempt, you 
can refer to the quit guide we provided you with (it is also on 
the Vula site) 
ATTENDANCE 
• You also receive the R50 show-up fee for attending today’s 
session 
• It’s great, and we really appreciate, that you attended today’s 
session 
• Because the show-up fee is for simply attending the session, 
you would obviously have received this, even if you weren’t 
abstinent in the past week 
• It’s important that you keep attending all your sessions, 
irrespective of whether you are abstinent in the previous week, 
because we don’t only care about whether you were abstinent, 
we also want to know, if you weren’t abstinent, when and how 
much you have been smoking in the previous week 
• That’s why, like with today’s session, you will receive the R50 
show-up fee at each session, irrespective of whether you 
remained abstinent in the previous week  
• Also remember that if you keep attending all sessions this term, 
you will receive R200 in the last session (in the last week of 
term), irrespective of whether you remained abstinent 
throughout the term 
• Thanks for coming to today’s session. We will see you at the 
same time next week. SUBJECT LEAVES. 
ABSTINENCE   
• For today’s session you receive the R150 payment 
because you were abstinent in the past week  
• Well done for remaining abstinent! 
• Because the R150 payment is for abstinence, you only 
receive it because you were abstinent in the past week 
• It’s great that you were abstinent in the past week EVEN 
THOUGH you weren’t abstinent at some point in the 
past term. The goal is to remain abstinent going forward.  
• Remember that if you are struggling to remain abstinent, 
you can refer to the quit guide we provided you with (it 
is also on the Vula site) 
ATTENDANCE 
• You receive the R50 show-up fee for attending today’s 
session 
• It’s great, and we really appreciate, that you attended 
today’s session 
• Because the show-up fee is for simply attending the 
session, you would obviously have received this, even if 
you weren’t abstinent in the past week  
• [If DID attend all four sessions] You attended all the 
sessions this term so you receive the R200 bonus 
payment  
• [If DIDN’T attend all four sessions] You unfortunately 
don’t receive the R200 bonus payment because you 
didn’t attend all your sessions this term 
• There are still two more follow-up sessions, but we will 
email you to sign up for them closer to the time. 
Remember that you will receive R200 for attending each 







Note: both previous abstinence & attendance = NA 
ABSTINENCE   
• For today’s session you unfortunately don’t receive the R150 
payment because you weren’t abstinent in the past week  
• Because the R150 payment is for abstinence, you only 
receive it if you are abstinent in the past week 
• Although you weren’t abstinent in the past week, the goal is 
to remain abstinent going forward. If, when you come in next 
week, we find that you are abstinent for the week prior, you 
will receive R150 payment for abstinence  
• Remember that, to help you get on track with your quit 
attempt, you can refer to the quit guide we provided you with 
(it is also on the Vula site) 
ATTENDANCE 
• You do still receive the R50 show-up fee for attending 
today’s session 
• It’s great, and we really appreciate, that you attended today’s 
session, even though you weren’t abstinent in the past week  
• Because the show-up fee is for simply attending the session, 
you obviously receive this even though you weren’t abstinent 
in the past week 
• It’s important that you keep attending all your sessions, 
irrespective of whether you are abstinent in the previous 
week, because we don’t only care about whether you were 
abstinent, we also want to know, if you weren’t abstinent, 
when and how much you have been smoking in the previous 
week 
• That’s why, like with today’s session, you will receive the 
R50 show-up fee at each session, irrespective of whether you 
remained abstinent in the previous week  
• Also remember that if you keep attending all sessions this 
term, you will receive R200 in the last session (in the last 
week of term), irrespective of whether you remained 
abstinent throughout the term 
• Here is your payment for today; The R50 show-up fee. Please 
can you check the amount and sign the payment receipt. 
• Thanks for coming to today’s session. We will see you at the 
same time next week. SUBJECT LEAVES. 
ABSTINENCE   
• Unlike for week 1, for today’s session, you unfortunately don’t 
receive the R150 payment because you weren’t abstinent in the 
past week  
• Because the R150 payment is for abstinence, you only receive 
it if you are abstinent in the past week 
• Although you weren’t abstinent in the past week, the goal is to 
remain abstinent going forward. If, when you come in next 
week, we find that you are abstinent for the week prior, you will 
receive R150 payment for abstinence  
• Remember that, to help you get on track with your quit attempt, 
you can refer to the quit guide we provided you with (it is also 
on the Vula site) 
ATTENDANCE 
• You do still receive the R50 show-up fee for attending today’s 
session 
• It’s great, and we really appreciate, that you attended today’s 
session, even though you weren’t abstinent in the past week  
• Because the show-up fee is for simply attending the session, 
you obviously receive this even though you weren’t abstinent 
in the past week 
• It’s important that you keep attending all your sessions, 
irrespective of whether you are abstinent in the previous week, 
because we don’t only care about whether you were abstinent, 
we also want to know, if you weren’t abstinent, when and how 
much you have been smoking in the previous week 
• That’s why, like with today’s session, you will receive the R50 
show-up fee at each session, irrespective of whether you 
remained abstinent in the previous week  
• Also remember that if you keep attending all sessions this term, 
you will receive R200 in the last session (in the last week of 
term), irrespective of whether you remained abstinent 
throughout the term 
• Thanks for coming to today’s session. We will see you at the 
same time next week. SUBJECT LEAVES. 
ABSTINENCE   
• Unlike in previous weeks, for today’s session, you 
unfortunately don’t receive the R150 payment because 
you weren’t abstinent in the past week  
• Because the R150 payment is for abstinence, you only 
receive it if you are abstinent in the past week 
• Although you weren’t abstinent in the past week, the 
goal is to remain abstinent going forward.  
• Remember that if you are struggling to remain abstinent, 
you can refer to the quit guide we provided you with (it 
is also on the Vula site) 
ATTENDANCE 
• You receive the R50 show-up fee for attending today’s 
session 
• It’s great, and we really appreciate, that you attended 
today’s session 
• Because the show-up fee is for simply attending the 
session, you would obviously have received this, even if 
you weren’t abstinent in the past week  
• [If DID attend all four sessions] You attended all the 
sessions this term so you receive the R200 bonus 
payment  
• [If DIDN’T attend all four sessions] You unfortunately 
don’t receive the R200 bonus payment because you 
didn’t attend all your sessions this term 
• There are still two more follow-up sessions, but we will 
email you to sign up for them closer to the time. 
Remember that you will receive R200 for attending each 







 ABSTINENCE   
• For today’s session you unfortunately don’t receive the R150 
payment because you weren’t abstinent in the past week  
• Because the R150 payment is for abstinence, you only receive 
it if you are abstinent in the past week 
• Although you weren’t abstinent in the past week AND the week 
before that, the goal is to remain abstinent going forward. If, 
when you come in next week, we find that you are abstinent for 
the week prior, you will receive R150 payment for abstinence  
• Remember that, to help you get on track with your quit attempt, 
you can refer to the quit guide we provided you with (it is also 
on the Vula site) 
ATTENDANCE 
• You do still receive the R50 show-up fee for attending today’s 
session 
• It’s great, and we really appreciate, that you attended today’s 
session, even though you weren’t abstinent in the past week  
• Because the show-up fee is for simply attending the session, 
you obviously receive this even though you weren’t abstinent 
in the past week 
• It’s important that you keep attending all your sessions, 
irrespective of whether you are abstinent in the previous week, 
because we don’t only care about whether you were abstinent, 
we also want to know, if you weren’t abstinent, when and how 
much you have been smoking in the previous week 
• That’s why, like with today’s session, you will receive the R50 
show-up fee at each session, irrespective of whether you 
remained abstinent in the previous week  
• Also remember that if you keep attending all sessions this term, 
you will receive R200 in the last session (in the last week of 
term), irrespective of whether you remained abstinent 
throughout the term 
• Thanks for coming to today’s session. We will see you at the 
same time next week. SUBJECT LEAVES. 
ABSTINENCE   
• For today’s session you unfortunately don’t receive the 
R150 payment because you weren’t abstinent in the past 
week  
• Because the R150 payment is for abstinence, you only 
receive it if you are abstinent in the past week 
• Although you weren’t abstinent in previous weeks, the 
goal is to remain abstinent going forward.  
• Remember that if you are struggling to remain abstinent, 
you can refer to the quit guide we provided you with (it 
is also on the Vula site) 
ATTENDANCE 
• You receive the R50 show-up fee for attending today’s 
session 
• It’s great, and we really appreciate, that you attended 
today’s session 
• Because the show-up fee is for simply attending the 
session, you would obviously have received this, even if 
you weren’t abstinent in the past week  
• [If DID attend all four sessions] You attended all the 
sessions this term so you receive the R200 bonus 
payment  
• [If DIDN’T attend all four sessions] You unfortunately 
don’t receive the R200 bonus payment because you 
didn’t attend all your sessions this term 
• There are still two more follow-up sessions, but we will 
email you to sign up for them closer to the time. 
Remember that you will receive R200 for attending each 









Note: both previous abstinence & attendance = NA 
ABSTINENCE   
• Well done for remaining abstinent for the past week! 
• It’s great that you were abstinent in the past week, and the goal 
is to remain abstinent going forward.  
• Remember that if you are struggling with your quit attempt, 
you can refer to the quit guide we provided you with (it is also 
on the Vula site) 
ATTENDANCE 
• For today’s session, you receive the R50 show-up fee for 
attending today’s session 
• It’s great, and we really appreciate, that you attended today’s 
session 
• Because the show-up fee is for simply attending the session, 
you would obviously have received this, even if you weren’t 
abstinent in the past week 
• It’s important that you keep attending all your sessions, 
irrespective of whether you are abstinent in the previous week, 
because we don’t only care about whether you were abstinent, 
we also want to know, if you weren’t abstinent, when and how 
much you have been smoking in the previous week 
• That’s why, like with today’s session, you will receive the R50 
show-up fee at each session, irrespective of whether you 
remained abstinent in the previous week  
• Also remember that if you keep attending all sessions this 
term, you will receive R200 in the last session (in the last week 
of term), irrespective of whether you remained abstinent 
throughout the term 
• Here is your R50 show-up fee. Please can you check the 
amount and sign the payment receipt. 
• Thanks for coming to today’s session. We will see you at the 
same time next week. SUBJECT LEAVES. 
ABSTINENCE   
• Well done for remaining abstinent for the past week! 
• It’s great that you were abstinent in the past week AND the 
week before that. The goal is to remain abstinent going 
forward. 
• Remember that if you are struggling with your quit attempt, 
you can refer to the quit guide we provided you with (it is also 
on the Vula site) 
ATTENDANCE 
• For today’s session, you receive the R50 show-up fee for 
attending today’s session 
• It’s great, and we really appreciate, that you attended today’s 
session 
• Because the show-up fee is for simply attending the session, 
you would obviously have received this, even if you weren’t 
abstinent in the past week 
• It’s important that you keep attending all your sessions, 
irrespective of whether you are abstinent in the previous 
week, because we don’t only care about whether you were 
abstinent, we also want to know, if you weren’t abstinent, 
when and how much you have been smoking in the previous 
week 
• That’s why, like with today’s session, you will receive the 
R50 show-up fee at each session, irrespective of whether you 
remained abstinent in the previous week  
• Also remember that if you keep attending all sessions this 
term, you will receive R200 in the last session (in the last 
week of term), irrespective of whether you remained abstinent 
throughout the term 
• Thanks for coming to today’s session. We will see you at the 
same time next week. SUBJECT LEAVES. 
ABSTINENCE   
• Well done for remaining abstinent for the past week! 
• It’s great that you were abstinent in the past week AND 
the weeks before that. The goal is to remain abstinent 
going forward. 
• Remember that if you are struggling to remain abstinent, 
you can refer to the quit guide we provided you with (it 
is also on the Vula site) 
ATTENDANCE 
• You receive the R50 show-up fee for attending today’s 
session 
• It’s great, and we really appreciate, that you attended 
today’s session 
• Because the show-up fee is for simply attending the 
session, you would obviously have received this, even if 
you weren’t abstinent in the past week  
• [If DID attend all four sessions] You attended all the 
sessions this term so you receive the R200 bonus 
payment  
• [If DIDN’T attend all four sessions] You unfortunately 
don’t receive the R200 bonus payment because you 
didn’t attend all your sessions this term 
• There are still two more follow-up sessions, but we will 
email you to sign up for them closer to the time. 
Remember that you will receive R200 for attending each 






 ABSTINENCE   
• Well done for remaining abstinent for the past week! 
• It’s great that you were abstinent in the past week EVEN 
THOUGH you weren’t abstinent in the week before that. The 
goal is to remain abstinent going forward.  
• Remember that if you are struggling with your quit attempt, 
you can refer to the quit guide we provided you with (it is also 
on the Vula site) 
ATTENDANCE 
• For today’s session, you receive the R50 show-up fee for 
attending today’s session 
• It’s great, and we really appreciate, that you attended today’s 
session 
• Because the show-up fee is for simply attending the session, 
you would obviously have received this, even if you weren’t 
abstinent in the past week 
• It’s important that you keep attending all your sessions, 
irrespective of whether you are abstinent in the previous 
week, because we don’t only care about whether you were 
abstinent, we also want to know, if you weren’t abstinent, 
when and how much you have been smoking in the previous 
week 
• That’s why, like with today’s session, you will receive the 
R50 show-up fee at each session, irrespective of whether you 
remained abstinent in the previous week  
• Also remember that if you keep attending all sessions this 
term, you will receive R200 in the last session (in the last 
week of term), irrespective of whether you remained abstinent 
throughout the term 
• Thanks for coming to today’s session. We will see you at the 
same time next week. SUBJECT LEAVES. 
ABSTINENCE   
• Well done for remaining abstinent for the past week! 
• It’s great that you were abstinent in the past week EVEN 
THOUGH you weren’t abstinent in [either/both] week 1 
and/or week 2.. The goal is to remain abstinent going 
forward.  
• Remember that if you are struggling to remain abstinent, 
you can refer to the quit guide we provided you with (it 
is also on the Vula site) 
ATTENDANCE 
• You receive the R50 show-up fee for attending today’s 
session 
• It’s great, and we really appreciate, that you attended 
today’s session 
• Because the show-up fee is for simply attending the 
session, you would obviously have received this, even if 
you weren’t abstinent in the past week  
• [If DID attend all four sessions] You attended all the 
sessions this term so you receive the R200 bonus 
payment  
• [If DIDN’T attend all four sessions] You unfortunately 
don’t receive the R200 bonus payment because you 
didn’t attend all your sessions this term 
• There are still two more follow-up sessions, but we will 
email you to sign up for them closer to the time. 
Remember that you will receive R200 for attending each 







Note: both previous abstinence & attendance = NA 
ABSTINENCE   
• In today’s session we found that you weren’t abstinent in the 
past week  
• Although you weren’t abstinent in the past week, the goal is to 
remain abstinent going forward.  
• Remember that, to help you get on track with your quit 
attempt, you can refer to the quit guide we provided you with 
(it is also on the Vula site) 
ATTENDANCE 
• You receive the R50 show-up fee for attending today’s session 
• It’s great, and we really appreciate, that you attended today’s 
session, even though you weren’t abstinent in the past week  
• Because the show-up fee is for simply attending the session, 
you obviously receive this even though you weren’t abstinent 
in the past week 
• It’s important that you keep attending all your sessions, 
irrespective of whether you are abstinent in the previous week, 
because we don’t only care about whether you were abstinent, 
we also want to know, if you weren’t abstinent, when and how 
much you have been smoking in the previous week 
• That’s why, like with today’s session, you will receive the R50 
show-up fee at each session, irrespective of whether you 
remained abstinent in the previous week  
• Also remember that if you keep attending all sessions this 
term, you will receive R200 in the last session (in the last week 
of term), irrespective of whether you remained abstinent 
throughout the term 
• Here is your R50 show-up fee. Please can you check the 
amount and sign the payment receipt. 
• Thanks for coming to today’s session. We will see you at the 
same time next week. SUBJECT LEAVES. 
ABSTINENCE   
• Unlike for week 1, for today’s session, we found that you 
weren’t abstinent in the past week  
• Although you weren’t abstinent in the past week, and the goal 
is to remain abstinent going forward.  
• Remember that, to help you get on track with your quit 
attempt, you can refer to the quit guide we provided you with 
(it is also on the Vula site) 
ATTENDANCE 
• For today’s session, you receive the R50 show-up fee for 
attending today’s session  
• It’s great, and we really appreciate, that you attended today’s 
session, even though you weren’t abstinent in the past week  
• Because the show-up fee is for simply attending the session, 
you obviously receive this even though you weren’t abstinent 
in the past week 
• It’s important that you keep attending all your sessions, 
irrespective of whether you are abstinent in the previous 
week, because we don’t only care about whether you were 
abstinent, we also want to know, if you weren’t abstinent, 
when and how much you have been smoking in the previous 
week 
• That’s why, like with today’s session, you will receive the 
R50 show-up fee at each session, irrespective of whether you 
remained abstinent in the previous week  
• Also remember that if you keep attending all sessions this 
term, you will receive R200 in the last session (in the last 
week of term), irrespective of whether you remained abstinent 
throughout the term 
• Thanks for coming to today’s session. We will see you at the 
same time next week. SUBJECT LEAVES. 
ABSTINENCE   
• Unlike in previous weeks, for today’s session, we found 
that you weren’t abstinent in the past week  
• Although you weren’t abstinent in the past week, the 
goal is to remain abstinent going forward.  
• Remember that if you are struggling to remain abstinent, 
you can refer to the quit guide we provided you with (it 
is also on the Vula site) 
ATTENDANCE 
• You receive the R50 show-up fee for attending today’s 
session 
• It’s great, and we really appreciate, that you attended 
today’s session 
• Because the show-up fee is for simply attending the 
session, you would obviously have received this, even if 
you weren’t abstinent in the past week  
• [If DID attend all four sessions] You attended all the 
sessions this term so you receive the R200 bonus 
payment  
• [If DIDN’T attend all four sessions] You unfortunately 
don’t receive the R200 bonus payment because you 
didn’t attend all your sessions this term 
• There are still two more follow-up sessions, but we will 
email you to sign up for them closer to the time. 
Remember that you will receive R200 for attending each 







 ABSTINENCE   
• For today’s session, we found that you weren’t abstinent in 
the past week  
• Although you weren’t abstinent in the past week AND the 
week before that, and the goal is to remain abstinent going 
forward.  
• Remember that, to help you get on track with your quit 
attempt, you can refer to the quit guide we provided you with 
(it is also on the Vula site) 
ATTENDANCE 
• For today’s session, you receive the R50 show-up fee for 
attending today’s session  
• It’s great, and we really appreciate, that you attended today’s 
session, even though you weren’t abstinent in the past week  
• Because the show-up fee is for simply attending the session, 
you obviously receive this even though you weren’t abstinent 
in the past week 
• It’s important that you keep attending all your sessions, 
irrespective of whether you are abstinent in the previous 
week, because we don’t only care about whether you were 
abstinent, we also want to know, if you weren’t abstinent, 
when and how much you have been smoking in the previous 
week 
• That’s why, like with today’s session, you will receive the 
R50 show-up fee at each session, irrespective of whether you 
remained abstinent in the previous week  
• Also remember that if you keep attending all sessions this 
term, you will receive R200 in the last session (in the last 
week of term), irrespective of whether you remained abstinent 
throughout the term 
• Thanks for coming to today’s session. We will see you at the 
same time next week. SUBJECT LEAVES. 
ABSTINENCE   
• For today’s session, we found that you weren’t abstinent 
in the past week  
• Although you weren’t abstinent in previous weeks the 
goal is to remain abstinent going forward.  
• Remember that if you are struggling to remain abstinent, 
you can refer to the quit guide we provided you with (it 
is also on the Vula site) 
ATTENDANCE 
• You receive the R50 show-up fee for attending today’s 
session 
• It’s great, and we really appreciate, that you attended 
today’s session 
• Because the show-up fee is for simply attending the 
session, you would obviously have received this, even if 
you weren’t abstinent in the past week  
• [If DID attend all four sessions] You attended all the 
sessions this term so you receive the R200 bonus 
payment  
• [If DIDN’T attend all four sessions] You unfortunately 
don’t receive the R200 bonus payment because you 
didn’t attend all your sessions this term 
• There are still two more follow-up sessions, but we will 
email you to sign up for them closer to the time. 
Remember that you will receive R200 for attending each 




ROBUSTNESS: ALTERNATIVE MODELS 
 Model B:I Model B:II Model B:III 
 Pooled Probit RE Poisson Pooled Negative Binomial  
Treatment 0.217*** 0.388 0.428 
 (0.047) (0.490) (0.533) 
Age 0.032** -0.300** -0.337** 
 (0.015) (0.151) (0.149) 
Male 0.017 1.018* 1.319** 
 (0.069) (0.576) (0.536) 
Coloured 0.082 0.864 1.136* 
 (0.062) (0.670) (0.674) 
Indian 0.052 -0.327 -0.231 
 (0.070) (0.703) (0.687) 
White 0.239*** 0.495 0.107 
 (0.069) (0.713) (0.690) 
Income (ln) -0.05 0.437 0.381 
 (0.043) (0.407) (0.432) 
Intervention period  -6.318*** -6.515*** 
  (0.444) (0.657) 
3-month follow-up  -3.982*** -4.109*** 
  (0.499) (0.706) 
Smoking duration -0.031 0.546*** 0.582*** 
 (0.019) (0.167) (0.194) 
Smoking intensity 0.002   
 (0.005)   
FTCD score 0.017 0.783*** 0.819*** 
 (0.016) (0.150) (0.168) 
MTWS-R score -0.001 0.028 0.034 
 (0.002) (0.019) (0.024) 
Baseline CO reading -0.003 0.032 0.046 
 (0.002) (0.031) (0.038) 
Quit attempt in past 5 years 0.124** -0.659 -0.406 
 (0.051) (0.578) (0.713) 
SASEQ score 0.007 0.032 0.011 
 (0.007) (0.054) (0.059) 
Importance of current quit attempt 0.006 -0.309 -0.48 
 (0.037) (0.388) (0.407) 
Determination for current quit 0.013 -0.762* -0.856* 
 (0.038) (0.445) (0.444) 
RFQ intrinsic score -0.019 0.172 0.09 
 (0.019) (0.172) (0.190) 
RFQ extrinsic score 0.021 -0.129 0.187 
 (0.029) (0.263) (0.275) 
N 430 361 361 
log-likelihood -147.46634 -854.11868 -851.50556 
* p<0.10, ** p<0.05, *** p<0.01    
Standard errors in parentheses. SEs are clustered in Model B:I and B:III 
Marginal effects reported    
 
